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ABSTRACT 
Antiretrovirals (ARVs) can find clinical application for both treatment and pre-
vention of HIV infection. Pre-exposure prophylaxis (PrEP) strategies have been re-
cently introduced to protect individuals who are at high risk of acquiring HIV infec-
tion. The majority of existing ARVs are oral formulations which necessitate lifelong 
daily dosing and suboptimal adherence to this dosing regimen could result in devel-
opment of viral resistance against treatment. Long-acting injectable (LAI) nanofor-
mulations administered either intramuscularly or subcutaneously could be a valuable 
pharmacological option. LAIs could potentially simplify dosing regimen, reducing 
the total amount of drug consumed thus reducing the oral cost of treatment/PrEP and 
most importantly addressing the problem of suboptimal adherence. The development 
of novel LAI therapies is complicated by several pharmacological factors including 
ARV pharmacokinetics and compatibility with existing formulation strategies. The 
overall aim of this thesis was to investigate and simulate the pharmacokinetics of LAI 
formulations in order to provide effective tools to inform the future development of 
formulations. 
A number of different strategies to investigate the pharmacokinetics of LAI for-
mulations were developed in this thesis. Physiologically based pharmacokinetic 
(PBPK) modelling represents the mathematical description of anatomical, physiolog-
ical and molecular processes that define pharmacokinetics in humans.  In the recent 
past, PBPK models have been developed for several disease areas to simulate phar-
macokinetics in humans, which currently play an active role in the design of clinical 
trials and regulatory approvals. In Chapter 2, human adult PBPK models have been 
developed and validated against clinically available pharmacokinetic data of oral for-
mulations for eight ARVs. These validated models were then used to identify theo-
retical optimal dose and release rates of LAI formulations for weekly and monthly 
administration. Clinical studies in paediatric patients encounters ethical issues and 
possesses concerns during dose optimization. In Chapter 3 and 4, PBPK models have 
been developed and validated for children and adolescents for existing LAI formula-
tions of cabotegravir and rilpivirine. Doses were optimised for monthly administra-
tion such that the plasma concentrations stay over the assumed target concentrations, 
for paediatric population according to different weight groups recommended by 
World Health Organisation. In Chapter 5, experimental methods (static release dialy-
sis, sample-and-separate method and dynamic release dialysis) to evaluate the drug 
release rate from the site of injection were developed. The in vitro release rates were 
correlated with clinical release rates to obtain a mathematical equation describing the 
in vitro in vivo extrapolation (IVIVE) in Chapter 6. 
Novel computational and experimental methods to support the development and 
optimisation of LAI formulations are required. These findings represent valuable ap-
plications of novel methods to simulate and characterise the pharmacology of LAI 
formulations. The reported findings could help simplify ARV dosing strategies by 
providing an initial dosing guideline for clinical trials in humans. This approach could 
improve therapy thus addressing the problem of suboptimal adherence and reduce 
cost of overall treatment. PBPK models and IVIVE could be an innovative strategy 
to evaluate drug pharmacokinetics in humans and optimise dose and release rates of 
novel formulations for LAI HIV therapy.  
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1.1. Human immunodeficiency virus  
Human immunodeficiency virus (HIV) is a retrovirus and since its discovery in 
1983, it has infected an estimated total of 75 million people globally [1, 2]. Among 
them 36.9 million people are currently living with HIV and 2 million people were 
infected in 2014, a 35 % decrease in the number of new infections compared to the 
year 2000 indicating that there is a remarkable progress in controlling the spread of 
this infection [3]. In 1996, UNAIDS was formed to limit virus diffusion by identifying 
preventive and therapeutic strategies, with the target  of providing treatment access to 
every HIV infected individual by 2030 [3, 4].  
Although HIV was discovered more than 30 years ago, treatment and prevention 
strategies can be characterised by suboptimal efficacy and side effects [5]. This is 
mainly due to lack of understanding of the pathophysiological mechanisms of infec-
tion and optimal pharmacological tools to inhibit viral replications [6]. The progress 
in HIV research has almost doubled with the number of articles reaching up to 16,317 
in the year 2015 compared to 9,991 in 2000 [7]. Efforts are currently in progress to 
design vaccines that could prevent the virus from infecting HIV-negative individuals 
[8-10]. 
1.2. HIV Life Cycle  
HIV is a lentivirus which belongs to the family Retroviridae, known for causing 
various neuro- and immunological conditions in humans [11]. This particular class of 
virus requires long incubation times in the host and the infection progresses to ac-
quired immunodeficiency syndrome (AIDS) in less than a decade without medication 
[12]. The primary receptor for HIV is CD4 antigen, which is expressed on CD4+ T 
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lymphocytes and macrophages – cells of the immune system [13]. HIV has the capa-
bility to transfer its ribose nucleic acid (RNA) strands through an intact nuclear mem-
brane in an infected cell thus gaining an advantage of replication in terminally differ-
entiated cells, a unique ability among its family of viruses [12, 14]. 
The outer membrane of HIV is a bilayer consisting of important components that 
assist in gaining access to the host cell [15]. Trimers of glycoprotein gp120 and gp41 
are expressed on the surface of the viral membrane [13]. The inner portion of the 
bilayer is lined with the gag protein which constitutes a 7 nm thick matrix [16]. More-
over the internal core of the virus contains a conical shaped shell, called the capsid 
with several copies of key enzymes and proteins such as the integrase, reverse tran-
scriptase (RT), nucleocapsid, viral protein and two copies of RNA strands [16].  
HIV does not have the capability to reproduce by itself and therefore needs a suit-
able host cell i.e. humans [14]. The primary step after the successful transmission of 
HIV is binding of the virus to the cell membrane receptors of the target cells with the 
help of protein gp120 and the viral envelope protein present on its surface [17]. Dur-
ing the process of entry into the cell, the virus loses its outer membrane and only the 
core enters into the cytoplasm of the cell [12]. Once in the cytoplasm, the core under-
goes readjustments and releases the viral contents into the cytoplasm [11]. The RNA 
contents form a deoxyribose nucleic acid (DNA) complex in the cytoplasm with the 
assistance of reverse transcription complex [18]. The viral proteins send false signals 
to the nucleus of the infected cell to allow the newly formed DNA complex and other 
viral proteins through the nuclear membrane [19]. Utilising the help of integrase en-
zyme, the viral DNA is integrated with the cellular genome [20]. This process allows 
the production of viral proteins and RNA which are packed in the viral shell with the 
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help of protease enzymes to produce a mature virion thereby successfully constructing 
the replication of HIV virions through an infected cell. [11, 14, 17]. 
  
Figure 1.1 HIV life cycle in the cellular membrane of an infected cell [17] 
1.3. Antiretroviral therapy  
Antiretroviral (ARV) therapy can effectively control HIV replication rate and sup-
port the maintenance of low viral load in plasma and tissues [21]. This can also reduce 
the risk of viral transmission to other individuals. Extensive research through the 
years in the field of HIV facilitated the discovery of drugs that improve the survival 
rate of infected individuals similar to that of a healthy individual [22]. ARV therapy 
is based on the combination of three different ARVs from two of the five existing 
classes of ARVs, inhibiting the viral replication at different stages.  
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1.3.1. Entry inhibitors 
As previously described in section 1.2, HIV gains access to the T cells through the 
interaction of gp120 protein onto the CD4 receptor and the co-receptors CCR5 or 
CXCR4 [23]. The gp120 protein undergoes conformational changes when it interacts 
with CD4 receptor to expose the co-receptors. HIV gains access to the cytoplasm of 
the T cell using gp41 protein [24]. Entry inhibitors can effectively block the interac-
tion of viral proteins with CD4 receptor, inhibiting HIV entry into the host cell.   
Maraviroc is the first and only available entry inhibitor that blocks CCR5, but 
there is a possibility for HIV to access the CXCR4 co-receptor through other mecha-
nisms [25]. An alternative entry inhibitor - enfuvirtide, is a peptide which acts by 
forming a six-helix bundle with gp41 of the virus thus preventing any interaction with 
host cell [26].  
1.3.2. Nucleoside reverse transcriptase inhibitors (NRTIs) 
NRTIs target the reverse transcription process of HIV virus. Viral replication in-
volves the transcription of its RNA to DNA mediated by viral reverse transcriptase. 
Viral reverse transcriptase is typically not present in host cells, making it an ideal 
target for ARV therapy [27].  
NRTIs are competitive inhibitors of the viral RT and can successfully inhibit the 
synthesis of the viral DNA. NRTIs are prodrugs which convert to their active form – 
the di- or triphosphate analogues by host kinases to compete with the nucleotides in 
order to be used in this process  [28]. Zidovudine was the first clinically available 
NRTI and later several others such as abacavir, lamuvidine, tenofovir and emtricita-
bine have followed. Currently, tenofovir and emtricitabine are used widely as first-
line therapy drugs against HIV [29]. 
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1.3.3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
NNRTIs inhibit the reverse transcription process. Unlike NRTIs, NNRTIs inhibit 
RT non-competitively without the need of converting into its triphosphate form [30]. 
These are small molecules typically hydrophobic in nature and interfere with the viral 
transcription process by binding to a single position on the p66 subunit of the viral 
RT protein. This hinders the ability to handle endogenous nucleosides and nucleotides 
during reverse transcription, thereby affecting the replication cycle [31].  
Classification of NNRTIs is divided into two categories – 1st and 2nd generation. 
The drugs in the 1st generation consist of nevirapine and efavirenz; and the 2nd gener-
ation include doravirine, etravirine and rilpivirine [29, 32]. 
1.3.4. Protease inhibitors (PIs) 
PIs inhibit maturation of the immature virions. Post transcription, the immature 
viral RNA and viral proteins migrate to the cytoplasm of the host cell from the endo-
plasmic reticulum. Viral protein shell is synthesized using the infected cellular com-
ponents. Detachment of the viral components from the host cell is defined as the mat-
uration stage. Protease enzymes cleave peptides to specific chain lengths that are cru-
cial viral components. PIs target these enzymes thus preventing the packing of essen-
tial peptides during the viral replication. The main precursor proteins such as gag and 
RT are targeted in this process [34]. 
Amprenavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir and 
saquinavir are the first generation PIs; atazanavir and darunavir are the 2nd generation 
PIs, which are highly potent against HIV [29]. 
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1.3.5. Integrase inhibitors 
Integrase inhibitors target the integration process of the viral DNA post reverse 
transcription. Viral integrase enzyme plays a key role in DNA integration with the 
host DNA. Integrase inhibitors bind to the viral enzyme inhibiting its function and 
interrupting viral replication [28]. 
Raltegravir was the first integrase inhibitor approved for clinical use [35]. Later 
dolutegravir, elvitegravir and cabotegravir followed[29, 36]. 
1.4. Highly Active Antiretroviral Therapy (HAART) 
HAART is a strategy designed to address the problem of viral resistance to ARVs. 
During HIV replication, the virus undergoes various mutations due to its inability to 
proofread the enzymes produced in the host cell. This leads to various mutated HIV 
strains and although most of them are inferior to the parent HIV and not harmful, few 
may develop resistance to antiretroviral therapy (ART) thus making the treatment in-
effective [37]. Combinational therapy with drugs from different classes are given to 
patients to address this problem. 
HAART generally consists of a combination of three drugs having synergistic ef-
fect to successfully suppress viral replication. Factors influencing drug combinations 
include total viral load, CD4 T cell count, survivability and occurrence of other op-
portunistic infections [38]. HAART reduces the probability of spontaneous mutation 
strains thereby lowering chances of the virus gaining resistance. Currently HAART 
is available as a single tablet consisting of multiple drugs. A few combinations are 
shown in Table 1.1. 
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Table 1.1. Various combinations of fixed dose combinations approved in the past 
12 years for use in ART [29] 
Brand Name Combination Approval date 
Epzicom Abacavir and lamivudine August 2, 2004 
Truvada 
Emtricitabine and tenofovir disoproxil 
fumarate 
August 2, 2004 
Atripla 
Efavirenz, emtricitabine, and tenofovir 
disoproxil fumarate 
July 12, 2006 
Complera 
Emtricitabine, rilpivirine, and tenofovir 
disoproxil fumarate 
August 10, 2011 
Stribild 
Elvitegravir, cobicistat, emtricitabine, and 
tenofovir disoproxil fumarate 
August 27, 2012 
Triumeq Abacavir, dolutegravir, and lamivudine August 22, 2014 
Evotaz Atazanavir and cobicistat January 29, 2015 
Prezcobix Darunavir and cobicistat January 29, 2015 
Genvoya 
Elvitegravir, cobicistat, emtricitabine, and 
tenofovir alafenamide fumarate 
November 5, 2015 
 
Prevention strategies are also being implemented in addition to treatment. Pre-
exposure prophylaxis (PrEP) focuses on HIV-negative or uninfected individuals who 
are at high risk of acquiring HIV. Recently, Truvada® has been accepted for PrEP in 
addition to its use in ART [39]. It reduces the risk of HIV in healthy individuals up to 
92 % [40]. Other ARVs - rilpivirine and cabotegravir are currently being evaluated 
for PrEP in clinical trials [41, 42]. 
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1.5. Antiretroviral pharmacokinetics 
Pharmacokinetics is the study of what the body does to the administered drug 
through the description of drug distribution in tissues and organs. Plasma is the most 
frequently used biological matrix due to its ease of access and abundance, and plasma 
concentration represents an essential marker to describe drug exposure in the body 
[43]. The pharmacokinetic parameters that are commonly used to describe drug ex-
posure are: Cmax - the maximum concentration attained by the drug in plasma during 
a single dosing interval, Ctrough - the minimum concentration attained just before the 
following dose and AUC – the total area under the curve when the drug concentration 
is plotted against time (Figure 1.2). 
 
Figure 1.2 An example of a pharmacokinetic curve with time in hours on x-axis and 
concentration on y-axis. The arrows represent the key pharmacokinetic parameters – 
maximum concentration (Cmax), trough concentration (Ctrough) and area under the 
curve (AUC) shaded in blue. 
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The majority of the clinically available ARVs are administered orally with the 
exception of enfuvirtide which is administered as a subcutaneous (SC) injection twice 
daily thus restricting long-term usage [26].  
Drug pharmacokinetics is mediated by absorption, distribution, metabolism and 
elimination (ADME) processes in various organs and tissues. Some of the common 
pharmacokinetic terms used include bioavailability, drug clearance and induction and 
inhibition effects of drugs. Absolute bioavailability is the total fraction of drug reach-
ing the systemic circulation after administration. Poor bioavailability can lead to drug 
plasma concentrations not reaching the therapeutic range, rendering the medications 
unsuitable. Few causes include low solubility and low permeability leading to de-
creased oral absorption; extensive first-pass metabolism and high clearance rate [44]. 
Rapid metabolism and fast clearance are influenced by drug physiochemical proper-
ties such as low protein binding in plasma and low blood-to-plasma partition ratio 
[45]. Administering a drug metabolised by the same enzyme that competes for its 
degradation could address the problem of fast clearance. Ritonavir is a potent inhibitor 
of CYP3A4 - the most abundant enzyme in the body. PIs – atazanavir, darunavir and 
lopinavir are co-administered with ritonavir which boosts the absolute bioavailability 
of these drugs [46]. Tenofovir and emtricitabine are the most commonly used NRTIs 
- are hydrophilic in nature, have good absorption through the small intestine and also 
have longer mean plasma and intracellular half-lives to give a prolonged effect [47, 
48]. NRTIs are prodrugs which undergo phosphorylation after cell penetration to con-
vert into their active form for therapeutic outcome [49]. Cell penetration is the key 
requirement to interfere with the HIV life cycle and restrict the replication since most 
of the ARVs (except entry inhibitors) interfere with the replication process undergone 
inside the infected cell. Sanctuary sites are the places in the body where the drug 
 General Introduction 
12 
 
cannot penetrate but the virus can [50]. These represent a major challenge to com-
pletely eradicate viral replication. They are divided into two types depending on the 
sites – anatomical and cellular sanctuary sites. The anatomical sites include the central 
nervous system (CNS), genital tract, lymphatic circulation, spleen and lung. Dendritic 
cells, infected CD4+ cells and macrophages represent the cellular sanctuary sites [50, 
51]. 
Low drug absorption and high clearance leads to the requirement for higher dosing 
amounts thereby increasing the risk of side effects and cost of overall treatment [52]. 
Maintenance of drug concentrations in the therapeutic range is essential to suppress 
viral load and prevent viral resistance against therapy [53]. Raltegravir has high inter- 
and intra-patient variability where two efficacy studies failed therapy in 18 % and 33 
% patients with no evidence of HIV mutations, indicating raltegravir exposure and/or 
adherence could be the cause for treatment failure [54]. Combinational therapy may 
utilise small amounts of multiple drugs having synergistic effect, thus lowering the 
extent of side effects. Darunavir undergoes extensive intestinal and first-pass metab-
olism by CYP3A4 due to which it is administered along with ritonavir. Ritonavir 
boosts plasma concentrations of darunavir almost 11-fold by inhibiting its metabolism 
by CYP3A4 enzyme [55].  
Drug physiochemical properties play a vital role in reflecting their pharmacoki-
netic profiles. Lipinski’s “rule of 5” provides a summary of the ideal features a drug 
should possess to have a satisfactory ADME pattern. Intestinal absorption is highly 
dependent on drug permeability through the gut in addition to molecular properties 
such as log P, polar surface area and hydrogen bond donors. The extent of drug dis-
tribution is governed by protein binding, pKa and logP of the drug. Clearance of the 
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drug is affected by blood-to-plasma ratio, protein binding, volume of distribution and 
the drug’s ability to either induce or inhibit the metabolism in liver [56-58].  
Drug formulation research for safe administration is a challenging process. Day 
by day, drug delivery is facing more and more challenges, due to continuous growth 
in the number of water-insoluble drugs [60].  Type of drug delivery depends on factors 
such as onset time, drug targeting issues and drug characteristics such as stability and 
solubility [61]. Almost 40 % of the new molecules which are capable candidates for 
treatment are hydrophobic in nature, implying the necessity of an appropriate vehicle 
to transport the molecule passively or actively into the systemic circulation [62]. 
Reaching therapeutic concentrations without major side-effects at the site of action 
represents a key barrier in the pharmaceutical sector [63]. Absence of appropriate 
delivery agents that could deliver the drugs to their respective site of action drastically 
decreases the therapeutic potential of the active ingredient in vivo [64].  
Drug formulation includes excipients which assist the active pharmaceutical in-
gredient (API) in a number of ways. Examples of them include solubility enhancers, 
longer shelf-life, prevention of degradation in the stomach and specific tissue target-
ing agents  [65]. Design of appropriate formulation is dependent on the therapeutic 
requirement, ease of dosing and the route of administration. Broadly, routes of ad-
ministration are categorised into three types – enteral, parenteral and topical. Tablets, 
capsules, oral solutions, oral suspensions, oral emulsions, suppositories, sustained or 
delayed release tablets or capsules etc. are considered as enteral formulations as they 
are administered through the gastrointestinal tract. Intravenous, intramuscular (IM), 
intradermal, SC and intra-arterial are a few commonly used parenteral routes. Inhala-
tions, ophthalmic, ear and locally administered drugs on the skin (e.g. patches) are 
considered as topical routes. Numerous drug delivery templates have been designed 
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such as micro- or nanoparticles, micelles, dendrimers, polydendrons, liposomes etc. 
Each route of administration employs a drug delivery type that suits its purpose, for 
example – pulmonary administration of a vasodilator, 5(6)-carboxyfluorescein solu-
tion encapsulated as nanoparticles had prolonged action and targeted delivery than 
the free drug in an isolated rabbit lung model [66-69]. In a separate study, enhanced 
gene delivery of plasmid DNA was observed in bone-marrow derived mesenchymal 
stem cells of rat using multivalent-functionalised generation 5 poly(amidoamine) den-
drimers [70]. Elastic liposomes made from Epikuron 200 loaded with a potent anal-
gesic, ketorolac tromethamine, a hydrophilic drug showed increased penetration 
through the transdermal route [71]. 
Oral administration is the most widely used route of delivery due to its ease of 
administration [72]. Bioavailability was found to be low in conventional ARV formu-
lations [73] and efforts are in progress to improve the oral bioavailability of ARVs. 
Recently, solid drug nanoparticles (SDNs) were designed by freeze-drying emulsions 
with high drug loading and long-term stability [74]. These SDNs improved the appar-
ent permeability of efavirenz in caco-2 cells thereby potentially increasing the oral 
bioavailability close to four-fold (as predicted by the computational model). In rats, 
increased concentrations were observed with efavirenz SDNs compared with the ex-
isting formulation when dosed with the same amount of the drug [74]. In another 
study, atazanavir was prepared as a self-emulsifying system. In vitro studies indicate 
that the novel emulsion has three times higher dissolution rate compared to pure drug 
and in vivo studies in wistar rats show a two-fold increase in Cmax and AUC when 
compared to the pure drug [75].  
  
 General Introduction 
15 
 
1.6. Long-acting formulations 
Each route of administration has its own advantages and disadvantages. Long-
acting (LA) formulations address the essential problem of nonadherence in HIV pa-
tients. The two most commonly used routes of administration for LA formulations are 
IM and SC routes. Implants and osmotic pumps could also be an alternative option 
but these require personnel who are surgically experienced. This limits their use due 
to the cost, risk and time spent on a single patient and also shortage of healthcare 
personnel in remote areas leads to further complications [76, 77]. 
Drugs administered in-between the muscle are considered IM formulations and 
injections just below the subcutis, the area under the dermis and epidermis are SC 
formulations. Major difference between these two routes is the contact environment. 
Intramuscular, as the name suggests are mainly muscle cells surrounding the drug 
depot whereas adipose cells are the neighbours for drugs administered subcutane-
ously. Drug diffusion into the surrounding blood capillaries and lymph nodes is de-
pendent on the nature of the formulation – aqueous or non-aqueous. Drug diffusion 
in aqueous formulations is either solubility limited or restricted by polymers forming 
the micro- or nanoparticles. Oil, a common vehicle for non-aqueous formulations, 
could be an additional barrier for drug dissipation into systemic circulation to control 
its pharmacokinetic profile [78]. Toxicity profile for the drugs and excipients included 
in these formulations have to be evaluated extensively to ensure no adverse reactions 
and side-effects occur. 
IM and SC routes could be ideal resolutions for addressing issues such as ease of 
administration and cost of treatment. They provide alternative routes for drugs that 
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are insoluble or have low solubility due to their low absorption in the gut; and intra-
venous administration may have limited use as it does not provide sustained drug 
release and not suitable for insoluble drugs. Maintenance of drug concentrations for 
a long-period of time via IM or SC routes at therapeutic exposure utilises less drug in 
total as absorption through the gut and first pass metabolism are avoided thus making 
the overall treatment cost cheaper. Additionally, high exposure through oral formula-
tions could be avoided, reducing adverse effects seen with chronic daily-dosing [79, 
80].  
Existing ARVs necessitate life-long daily dosing and adherence to this dosing reg-
imen is essential to treat HIV. Suboptimal adherence places the patient at high risk of 
treatment failure or low protection rates in the case of PrEP strategies [81]. Nonadher-
ence to HIV therapy has been observed in an estimated 50 % to 70 % of patients who 
were prescribed multiple medications [82]. Currently ARV treatment has reduced to 
a mere one pill a day. Only 60-85 % patients adhered to the recommended dosing 
regimen due to forgetfulness, being busy or some other reason. There is difficulty in 
finding the perfect solution, although steps are taken to remind patients to administer 
the doses at regular intervals [83-85].  Use of LA formulations lasting multiple weeks 
or months, opens up the possibility of simplifying dosing regimens, increase adher-
ence, reduce the amount of drug consumed thus decreasing the overall cost and effec-
tiveness of treatment and PrEP [86]. 
The pharmacokinetics of a conventional oral formulation varies widely in a single 
dosing interval with plasma concentrations fluctuating from minimum effective con-
centration (MEC) to maximum safe concentration (MSC) (Figure 1.3). Suboptimal 
adherence to the prescribed dosing regimen can lead to HIV developing resistance 
against ART. A single dose of a LA formulation could result in sustained plasma 
 General Introduction 
17 
 
exposure solving the problem of suboptimal adherence observed with oral formula-
tions (Figure 1.4).  
Efforts are currently in progress to design LA formulations for HIV patients. Rilpi-
virine long-acting injectable (LAI) nanoformulation was developed in 2009 and the 
pharmacokinetic profile of IM and SC routes of administration in beagle dogs were 
compared. A similar pharmacokinetic profile after 12 weeks from the injection was 
described with a relatively lower Cmax and sustained release for SC compared to IM, 
however higher lymph concentrations in adjacent lymph nodes were observed with 
IM administration and were better tolerated compared to SC administration [86]. The 
same formulation was later tested in humans showed only 10-20 ng/ml decrement 
from the Cmax in drug plasma concentration between 3-6 months indicating potential 
in LA administration of ARVs [87]. Recently cabotegravir, an analogue of dolute-
gravir with a longer half-life, low metabolic clearance, low solubility and low daily 
dose was discovered that is capable of providing therapeutic drug exposure over a 
period of three months with an 800 mg formulation administered IM [36].  
 
Figure 1.3 Representative pharmacokinetics of a conventional oral formulation and 
suboptimal adherence are shown. 
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Figure 1.4 Representative pharmacokinetics of an ideal long-acting release formula-
tion.  
1.7. Pharmacokinetics of LAI formulations 
Depot formulations avoid three major processes undergone by oral formulations. 
These are drug dissolution, drug absorption through the gastrointestinal tract and first-
pass metabolism. These processes can significantly limit the drug absorption thus in-
creasing the overall amount administered [88]. Drug dissolution is a relevant step in 
drug delivery making it an influential aspect in discovery of any drug, particularly in 
the absorption phase for oral formulations. It also has importance in LA formulations 
as the major factor controlling the release of the drug from the depot. Evidence shows 
that only dissolved drug leaves the depot through the connective tissue for systemic 
distribution [79]. Drug absorption is dependent on the physicochemical properties of 
the drug and the excipients used in its formulation. Solubility and intestinal permea-
bility are the two important factors regulating the absorption process [65]. Also ex-
cipients such as solubility enhancers, membrane permeability enhancers used in the 
formulation could improve the net drug absorbed [89]. Absorption process also in-
cludes intestinal metabolism by CYP450 enzyme which further reduces the oral bio-
availability of drugs metabolised by this enzyme. These processes are avoided as the 
drug directly diffuses into the surrounding blood or lymph capillaries from the depot, 
thus escaping this process. First-pass metabolism eliminates a substantial amount of 
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drug at the entry point to the circulatory system. Subsequent to absorption, drug 
traverses through the portal vein from the small intestine to the liver. Liver hepato-
cytes metabolise the drug and only a fraction passes through the heart for systemic 
distribution [90]. In few cases, depending on the drug properties, chronic usage of 
oral formulations can lead to hepatotoxicity in the long-term due to extensive usage 
of hepatocytes in the metabolic process. This step is also eluded in these two routes 
which further reduces the quantity of drug utilised [91, 92]. 
There is no ideal route for drug delivery as each have their advantages and disad-
vantages. Discontinuation of therapy could be complicated as the depot has to be re-
moved surgically which require experienced personnel. Drug absorption from the de-
pot could be hampered if the area is poorly accessible for blood capillaries [93]. Local 
pain and swelling was observed initially at the site of injection which can cause dis-
comfort and irritation in patients [94]. In some cases, there is a possibility of potential 
muscle damage at the site. Individuals having fear of injections would not be compli-
ant with this route of delivery. Special populations such as neonates, infants and in-
dividuals with abnormally low muscle or adipose tissues pose a risk which can hinder 
the treatment. Although these routes have disadvantages, they make it an interesting 
and attractive way to deliver drugs cost effectively with reduced side-effects com-
pared to oral administration [95]. 
LAI formulations represent an innovative strategy to improve the administration 
of ARVs. Although they could provide an effective alternative to the problems en-
countered with current oral therapy, the design of novel formulations is challenging. 
These formulations have to ensure that the therapeutic efficacy is maintained during 
the dose interval otherwise HIV might attain resistance against the therapy. Release 
rate is one of the key parameters in designing LA formulations. Rate of release could 
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be affected by numerous factors and a few major influencing factors include dissolu-
tion rate of drug, protein binding, particle size, dosage and hepatic clearance. 
1.7.1. Clearance 
Extent of drug clearance is associated with the concentration of drug present in 
blood plasma. More drug in plasma increases the amount of drug cleared which can 
be perceived with oral formulations where the plasma concentration increases to Cmax 
and decreases to Ctrough in a short span of time. A similar situation occurs with LA 
formulations - the higher the release rate the greater the clearance. Dose and release 
rate optimisation should be essential so that therapeutic exposure is achieved for the 
desired time period [58]. 
1.7.2. Dissolution rate 
Dissolution is an essential part of any formulation. Undissolvable drug is of no 
use for medical purpose. Rate of dissolution should be higher in the case of oral com-
pared to LA formulations as there is limited time in the small intestine for absorption. 
The designed formulations should disintegrate and dissolve rapidly for effective ab-
sorption. Excipients play an important role in improving the disintegration and disso-
lution rate of the formulation (e.g. disintegrating agents, solubility enhancers). Con-
trolled release rate is desirable in LA formulations, as the drug is expected to diffuse 
at a slower pace just enough to maintain therapeutic concentrations for an extended 
time. Excipients also influence the release rate - with hydrophilic or lipophilic poly-
mers, the release rates of the active ingredients from the formulation could be in-
creased or decreased [96]. The drug to excipient ratio had a significant effect on the 
release of atenolol from hydroxypropylmethylcellulose (HPMC) polymeric matrices 
[97] and also the release of paclitaxel from nanoparticles formulated with varying 
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ratios of hydrophilic/lipophilic polymers and surfactants indicate the importance of 
excipients in controlling drug dissolution [98]. 
1.7.3. Dose 
Dosage plays an important role in maintaining therapeutic exposure of a drug. The 
amount administered into the muscle or SC area should be tolerable. Literature shows 
that the maximum dose that has been injected and well tolerated in an individual is 
1.5 g of cefuroxime formulation [99]. Larger doses attract higher amounts of immune 
cells to the depot site, leading to the formation of a granuloma, which could be bene-
ficial in further controlling the drug release rate and might facilitate the drug to the 
lymphatic system [79]. Utilisation of optimal doses is essential for use in therapy to 
reduce potential occurrence of toxicological and adverse events. 
1.7.4. Particle size 
Particles can be prepared either using bottom-up approach (e.g. self-assembly) or 
top-down approach (e.g. milling). Spherical particles undergo relatively faster and 
uniform dissolution than irregularly shaped particles. Particle size influences the sur-
face area exposed to the surrounding body fluid at the site of depot. Increase in surface 
area leads to more contact with blood or lymph at the depot, facilitating the dissolution 
process of the active ingredient, thereby increasing drug exposure in plasma [100].  
1.7.5. Protein binding 
Drug release rate is influenced by protein binding in a number of ways. High pro-
tein affinity of the drug can increase the release rate at the site of depot and in plasma, 
the available free drug decreases, which in turn reduces metabolic clearance. This 
leads to an increase in half-life thus prolonging therapeutic exposure. Protein binding 
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also influences the extent of drug distribution and the steady-state volume of distri-
bution [101]. There is evidence of nanoparticle binding to proteins which can further 
change the drug biodistribution profile and alter the immunogenicity due to the for-
mation of a protein corona [102].  
1.8. Physiologically Based Pharmacokinetic (PBPK) Modelling 
Discovery of novel drugs and developing them into potential formulations typi-
cally consumes a substantial amount of time. Balance between physiochemical prop-
erties and ADME underpins the safety aspects during treatment. Essential compo-
nents include safety and efficacy profile, low systemic toxicity and no or mild long-
term adverse effects [56]. Only 18 % of the drugs in infectious diseases category tend 
to get accepted for clinical trials out of which less than 15 % percent reach the market 
[59]. The drug discovery phase is commonly followed by preclinical and clinical trials 
before reaching larger populations. These steps necessitate drug companies to invest 
largely in a single drug to reach the pharmaceutical market and intermittent failure 
during clinical studies leads to significant loss of time and money. Mathematical mod-
els were designed to tackle some of these key situations, which provide a rough esti-
mate of the pharmacodynamics or pharmacokinetics of medications in humans prior 
to preclinical and clinical studies [103]. Various models have been used ever since 
that can identify the potential factors influencing the pharmacokinetic-pharmacody-
namic profiles of novel drugs. Although there are quite a few models which use clin-
ical data to compute ADME parameters, PBPK models have a unique feature which 
use only in vitro data to extrapolate the pharmacokinetics in humans [104]. However, 
the quality of the end result from the PBPK model depends on the quality of the in 
vitro data used in these models, suggesting the importance of the standardisation of 
in vitro assays. The concept of PBPK modelling dates back to the year 1937, but 
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complexities associated with computations due to the lack of workstations limited the 
use of these models until now [105]. The use of PBPK modelling is on the rise, with 
33 Federal Drug Administration (FDA) applications having simulated data between 
2008 – 2013 [106]. 
In vitro – in vivo extrapolation is a bottom-up method which combines various 
data types such as anatomical and physiological parameters of a population, drug pa-
rameters (e.g. protein binding, lipophilicity, solubility and absorption rate) to evaluate 
the four crucial factors - ADME with mathematical equations, commonly termed as 
PBPK modelling [50]. In vitro studies such as apparent permeability, intrinsic clear-
ance using baculosomes, octanol-to-water partition coefficient are performed for the 
desired drug and then extrapolated to human data using mathematical equations. 
These in vitro data help in computing parameters such as net absorption rate from the 
apical to basolateral side of the small intestine, total hepatic clearance, volume of 
distribution, induction and inhibition activity of CYP450 metabolising enzymes etc. 
[57, 107, 108]. All these parameters assist in precisely determining the pharmacoki-
netic profiles of drugs in different tissues of the human body. PBPK models have the 
ability to simulate the pharmacokinetics of drugs administered through different 
routes including oral, intravenous, transdermal etc. There are different versions of the 
models, broadly divided into open and closed sourced. Users having freedom to con-
struct and customise their own models with the help of an application are termed as 
open sourced, for e.g. Berkeley Madonna™, MATLAB®, python™, NONMEM®. 
But the user needs appropriate training in order to use these applications where are 
models are built from scratch and are usually time consuming. Readily available mod-
els provide simple and user friendly interface and are also less time consuming which 
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however are expensive and are marketed by companies such as Simcyp®, Gas-
troPlusTM, and PKSIM® which restrict the usage in terms of flexibility and charge the 
user for the provided service [50, 109]. 
PBPK models utilise the concept of compartments to denote the organs and tissues 
of the human body. These are connected to each other by means of predetermined 
mathematical equations representing the kinetics between the two compartments. 
Basic PBPK model can be represented with three compartments: one representing the 
blood plasma concentrations, the second one representing the metabolism processes 
occurring in liver and the final one representing the tissues of the body which is in 
equilibrium with the first compartment (Figure 1.5). Once the drug reaches the plasma 
compartment after the initial absorption process, simultaneous distribution to tissue 
reservoirs and metabolism in liver kick in to eliminate a fraction of the drug [110]. 
This process advances in a continuous cycle until all of the drug is either metabolised 
or excreted and eliminated by the body. Dosing schedules can also be accommodated 
to simulate fixed or variable dose therapies in virtual individuals. Researchers are 
currently expanding this basic model into a whole-body PBPK model where a single 
tissue represents a single compartment (Figure 1.7). This way, identification of phar-
macokinetics for each and every tissue is possible and a comprehensive report is ob-
tained [111].  
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Figure 1.5 Example of a simple PBPK model consisting three compartments to meas-
ure the pharmacokinetics of a drug in plasma. 
Key details could be identified such as affinity of the drug to a particular tissue(s), 
extent of drug penetration into various layers of a tissue, influence of gastrointestinal 
transit times in adults vs. children, effect of variable clearance rates among different 
alleles, drug-drug interactions, different routes of administration and various types of 
formulations (Figure 1.6). Safety and efficacy of drug exposure-response in a partic-
ular tissue could be quantified and evaluated along with identification of intracellular 
concentrations. Tissue penetration could identify potential drugs that pass through 
inaccessible sites such as brain, spinal cord, testes, lymphatic system and also analyse 
their respective concentrations, which could be difficult to observe in vivo. This fea-
ture could be helpful in identifying the reach of ARVs across both anatomical and 
cellular sanctuary sites [112]. Lack of information on various drug-drug interactions 
could be investigated using PBPK modelling and the doses could be optimised ac-
cordingly. Dose adjustments were suggested for artemether which requires 160 mg 
more of the antimalarial drug to induce a similar effect when administered in combi-
nation with efavirenz [113, 114]. Genetic variations affecting the clearance of the drug 
could result in toxicity or under exposure which can be addressed with modelling to 
inform optimal doses needed for appropriate therapy. Xu et al. have used clinical data 
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to validate PBPK models at different clearance rates of efavirenz observed for differ-
ent CYP2B6 alleles [115]. Pharmacokinetics of clopidogrel and its active metabolite 
were predicted and compared in populations with CYP2C19 genetic polymorphisms 
having slow, intermediate, rapid and ultrafast clearance rates [116]. Different age 
groups can be segregated and an optimum dose could be informed in special popula-
tion, decreasing the toxicity profile of drugs and adverse effects in chronic dosing. 
Potential routes of administration could be compared and the optimal dose to reach 
therapeutic efficacy could be informed along with the study of the interaction between 
formulation and human environment [111].  
 
Figure 1.6 A flow chart representing the summary of various factors that can be eval-
uated with a PBPK model using physiochemical parameters of the drug, anatomical 
and physiological parameters of an individual. (Adapted from Moss et al. 2015 [111]) 
PBPK models can predict a virtual population if variability is introduced into the 
parameters of the model. It would be possible to examine the effect of one constraint 
on the drug pharmacokinetics by performing sensitivity analysis to identify the influ-
encing physicochemical parameter during drug discovery process [117]. In addition, 
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the pharmacodynamic profile could be scrutinized when PBPK models are combined 
with in vivo parameters to identify non-toxic drug levels required for therapeutic ex-
posure [111].  
 
Figure 1.7 A whole-body PBPK model representing various tissues and organs in 
compartments. Small intestine was divided into seven compartments for effective ab-
sorption. Each line in the figure represents a first-order kinetic equation which com-
putes the distribution of drug through the tissues. [118-120] 
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1.9. Aims 
The overall aim of the thesis was to generate innovative computational and exper-
imental methods to support the rational design of LAI formulations. The clinical suc-
cess of LA administration strategies can be deeply influenced by multiple factors in-
cluding pharmacokinetics and formulation characteristics. Consequently, a compre-
hensive understanding of ARV pharmacology, suitable experimental methods for the 
characterisation of formulation properties and predictive pharmacokinetic models for 
the simulation of clinical scenarios can represent valuable tools to inform the design 
of novel LA strategies. Novel PBPK models for virtual adult and paediatric popula-
tions were developed to identify the optimal dose and release rates for ARVs. Addi-
tionally, the release rate of existing LAI formulations was determined using in vitro 
methods in order to extrapolate the values to human parameters through in vitro-in 
vivo extrapolation (IVIVE).  
The main objective of Chapter 2 was to design and construct a novel PBPK model 
for the simulation of the pharmacokinetics of most commonly used ARVs to hypoth-
esise the potential use of LAI IM formulations in adults. Optimal dose and release 
rates were identified for eight different ARVs. The following study in Chapter 3 was 
to design and validate a PBPK model for paediatric patients aged 3-18 years, provid-
ing a comprehensive mathematical evaluation of physiological and anatomical char-
acteristics of children and adolescents. Further to the validation, in Chapter 4, simu-
lations were performed to inform the dose of cabotegravir and rilpivirine LAI formu-
lations in children and adolescents. Informed dose in paediatric individuals was sim-
ulated for standard weight categories according to World Health Organization (WHO) 
guidelines.  
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Drug release from three in vitro methods for LAI formulations were evaluated in 
Chapter 5. In vitro experiments were performed with four different clinically availa-
ble LAI formulations to identify the release rate from formulations. PBPK models for 
the four formulations were constructed and the predicted release rates were compared 
against in vitro release rates to inform IVIVE in Chapter 6, in order to develop an 
integrated approach for the prediction of the pharmacokinetics of future LAI formu-
lations.  
  
 
 
CHAPTER 2  
2. Optimisation of intramuscular 
dose and release rate for long-
acting nanoformulations using 
PBPK modelling in adults   
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2.1. Introduction 
LAI formulations of ARVs rilpivirine and S/GSK1265744/cabotegravir have been 
developed with the potential for once monthly dosing, or less frequently [121]. The 
development of the first LAI ARV formulations has led to considerable interest 
amongst patients; a recent study found that 84 % of surveyed patients would definitely 
or probably try a once-monthly LAI ARV [122]. The LAI formulations are based on 
nanoparticulate suspensions milled with an average particle size of 200 nm for both 
these drugs [86, 123] which release the drug from the depot over a protracted period 
of time. The optimisation of nano-formulations for LA administration is complicated 
by several pharmacokinetic factors and has to take into account - the optimal dose and 
drug release into the circulation to achieve therapeutic or prophylactic plasma con-
centrations for the entire dosing interval. 
The pharmacokinetics of a drug are determined by processes that can be simulated 
through PBPK models. Specifically, PBPK can be used to predict pharmacokinetics 
as a function of formulation and route of administration [124]. These predictions can 
then inform the design of LAI formulations, identifying optimal characteristics in 
terms of dose and depot release rate. For ARVs, this modelling approach has been 
applied to identify factors influencing the pharmacokinetics of novel formula-
tions[74], the effect of genetics on drug distribution [125], pharmacokinetics in spe-
cial populations [126] and drug-drug interactions [127].  
The aim of this study was to simulate the pharmacokinetics of ARVs after admin-
istration of virtual IM LAI formulations using PBPK modelling. An open sourced 
software Matlab was used to design and develop PBPK models due to its ease of use 
with a minimal knowledge of programming languages. The PBPK models were first 
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validated against clinical data for oral counterparts, to assess the accuracy of the sim-
ulation. Theoretical target dose and release rate combinations for once weekly and 
once monthly IM administration were then identified.  
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2.2. Methods 
Virtual patients between the ages of 18 to 60 years were generated. All organs and 
tissues were represented as individual compartments. The model was based on the 
assumptions: 1) well-stirred compartments with instant distribution of the drug; 2) no 
oral drug absorption from the colon; and 3) the model is blood-flow limited. The 
PBPK model was designed using Simbiology v.4.3.1, a product of Matlab v.8.2 
(MathWorks, Natick, MA, USA 2013). The PBPK approach has been developed for 
key ARVs (two NRTIs, tenofovir and emtricitabine; three NNRTIs, efavirenz, rilpi-
virine and etravirine; two integrase inhibitors (IIs), raltegravir and dolutegravir and 
an unboosted protease inhibitor (PI), atazanavir. 
2.2.1. Anatomy 
The age, body mass index (BMI), and weight of the individual were initially de-
fined. Using allometric equations, the body surface area [128] and height are derived 
as follows:  
𝐻𝑒𝑖𝑔ℎ𝑡 (𝑖𝑛 𝑚) =
𝑊𝑒𝑖𝑔ℎ𝑡 (𝑖𝑛 𝑘𝑔)
𝐵𝑀𝐼 (𝑖𝑛 𝑚2/𝑘𝑔)
 
𝐵𝑜𝑑𝑦 𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑎𝑟𝑒𝑎 (𝑖𝑛 𝑚2)
= 𝑊𝑒𝑖𝑔ℎ𝑡 (𝑖𝑛 𝑘𝑔)0.425 × 𝐻𝑒𝑖𝑔ℎ𝑡 (𝑖𝑛 𝑐𝑚)0.725 × 0.007184 
These initial values were used for the calculation of organ and tissue volumes 
through allometric equations shown in Table 2.1a [129]. The blood circulation was 
represented by considering the cardiac output and regional blood flows as shown in 
Table 2.1b [130]. 
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Table 2.1a Allometric equations to compute the weights of each tissue and organ 
represented in kg [129] 
Adipose = ((((1.20*BMI)+(0.23*Age)-16.2)*Weight)/100) ± 0.041 
Blood = 3.33*BSA-0.81 ± 0.1 
Bones = exp(0.0689+2.67*log(Height)) ± 0.166 
Brain = 0.405*exp(-Age/629)*(3.68-2.68*exp(-Age/0.89)) ± 0.084 
Gonads = (3.3+53*(1-(exp((-Age/17.5)^5.4)))/1000 ± 0.049  
Heart = exp(-2.502+2.13*log(Height)) ± 0.069 
Intestines = exp(-1.351+2.47*log(Height)) ± 0.049 
Kidneys = exp(-2.306+1.93*log(Height)) ± 0.14 
Liver = exp(-0.6786+1.98*log(Height)) ± 0.028 
Lungs = exp(-2.092+2.1*log(Height)) ± 0.195 
Muscle = 0.93*Weight-Total weight 
Pancreas = exp(-3.431+2.43*log(Height)) ± 0.245 
Remaining = exp(-0.072+1.95*log(Height) ± 0.049 
Skin = exp(1.64*BSA-1.93) ± 0.049 
Spleen = exp(-3.123+2.16*log(Height)) ± 0.156 
Stomach = exp(-3.266+2.45*log(Height)) ± 0.0965 
Thymus= 14*((7.1-6.1*exp(-Age/11.9))*((0.14+0.86*exp(-Age/10.3))))/1000 ± 0.049 
Total weight = Lungs+Heart+Bones+Kidneys+Stomach+Intestines+Spleen+Pancreas+ 
Liver+Remaining+Brain+Skin+Blood+Adipose+Thymus+Gonads 
Age is in years, BMI is in kg/m2, BSA is in m2, height is in m, and weight is in kg 
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Table 2.1b Cardiac output and the blood flow reaching each organ and tissue 
represented as fraction of the cardiac output in L/h [130] 
Cardiac Output (in L/h) 15*(Weight^0.75) 
Adipose tissue 0.052 
Bones 0.042 
Brain 0.11 
Gonads 0.01 
Gut 0.05 
Hepatic artery 0.12 
Hepatic vein 0.32 
Kidneys 0.175 
Lungs 0.025 
Muscle 0.19 
Pancreas 0.05 
Portal vein 0.20 
Remaining tissues 0.01 
Skin 0.06 
Spleen 0.05 
Stomach 0.05 
Weight is in kg 
2.2.2. Intestinal Absorption 
A compartmental absorption and transit model has been integrated to simulate for 
oral drugs as previously described [118]. Absorption rate was evaluated using the 
apparent permeability obtained from caco-2 cells or the polar surface area (PSA) and 
hydrogen bond donor (HBD) values as previously described [131]. The IVIVE corre-
lation was obtained using 25 compounds with a standard protocol in order to evaluate 
the apparent permeability from caco-2 monolayers and comparing against in vivo val-
ues [57, 132]. The integrity of the monolayers was evaluated using transepithelial 
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electrical resistance (TEER) value (mean ~ 260 Ω cm2) and lucifer yellow as a non-
radioactive alternative [132]. 
2.2.3. Intestinal Metabolism 
The clearance of drugs in the gut (CLgut) was calculated considering the in vitro 
intrinsic clearance (CLint) and as an example, the abundance of cytochrome P450 fam-
ily 3, subfamily A (CYP3A) in the intestinal tissue (AbCYP3A) is given as follows [57, 
131]:  
CLgut (L/h)=
CLint × AbCYP3A × 1000 × 60
1000000
                                                             
The fraction of the drug transiting to the liver after metabolism in the gut (Fg) was 
computed using the following equation: 
Fg=
Qgut
Qgut  + fu,gut × CLgut
                                                         
where Qgut represents the blood flow to the gut and fu,gut is the fraction unbound in the 
gut. 
2.2.4. First pass metabolism 
The total intrinsic clearance (TCLint) of an enzyme was calculated as: 
TCLint=
CLint  × Abundance × Liver weight × MPPGL × 1000 × 60
1000000
          
where Abundance is the amount of enzyme present in a milligram of microsomal pro-
tein and MPPGL is amount of microsomal protein per gram of liver [107]: 
MPPGL = 101.407 + 0.0158 × Age - 0.00038 × Age
2 + 0.0000024 × Age3± 4          
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Then the sum of intrinsic clearances of all the enzymes that are metabolising the 
drug in the liver gives the total apparent clearance (CLapp):  
CLapp= ∑ TCLint
n
n=1                             
The systemic clearance (CL) is calculated from the blood and not the liver and is 
given by the equation: 
CL=
Qhv × fu × CLapp
Qhv+ CLapp × fu
          (6) 
where Qhv is the hepatic flow rate and fu is the fraction unbound in plasma. 
The fraction of the active drug that is available after first pass hepatic metabolism 
(Fh) is given as: 
Fh=1 - CL/Qhv               (7) 
2.2.5. Systemic Distribution  
The volume of distribution and systemic circulation was calculated using previ-
ously published equations [119, 133]. 
2.2.6. Intramuscular depot compartment 
A compartment was created to virtually represent the depot with a maximum vol-
ume of 6 mL, since it is the maximum volume of injection that has been previously 
used for IM administration, although lower volumes are usually needed for optimal 
tolerability. The blood flow to this area was calculated accordingly [99]. The release 
of the drug from the depot to the blood capillaries present in the muscle was given as 
[124]: 
d
dt
A= k × A         (8) 
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where A is the amount of drug released from the depot and k is the first-order release 
rate. A variability of ± 10 % for the release rate values was considered as it would be 
difficult to design nanoparticles with the exact release rate. 
2.2.7. Model validation  
The physicochemical properties of ARVs used to build the PBPK models are rep-
resented in Table 2.2. The models were primarily validated against clinical data at 
steady state for oral formulations of the ARVs (Table 2.3a, b). The model was also 
verified against an existing LAI formulation of rilpivirine [87]. The PBPK models 
were assumed to be qualified if the mean simulated value is ± 50 % from the mean 
clinically reported value.  
2.2.8. Prediction of pharmacokinetics following IM injection 
In the prediction of IM pharmacokinetics, the dose of the ARV and release rate 
were optimised such that the mean Ctrough was above the 90/95 % inhibitory concen-
tration (IC90, IC95) for wild type HIV virus or protein-binding adjusted inhibitory con-
centration (PAIC95) after 7- or 30-days after injection. A dose cut-off of 1500 mg was 
considered for IM administration. 
2.2.9. Prediction of Intracellular concentrations 
The active phosphate metabolite of tenofovir, tenofovir diphosphate (TFV-DP) 
intracellular concentrations were simulated as previously described [49]. The first or-
der elimination rate of emtricitabine triphosphate (FTC-TP) from the cellular com-
partment was calculated considering the half-life of FTC-TP [48]. The maximum up-
take velocity (Vmax) and maximum velocity of anabolism (km) were fitted to obtain a 
zero-order dose input rate (kin) such that the mean intracellular concentration of the 
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active metabolite at steady state (Css,avg) was in accordance to available clinical data 
following this equation:  
kin = (Vmax × C)/(km+ C)        (9) 
where C is the concentration in the plasma. 
Values of 0.9 ± 0.18 ng.h/ml and 18 ± 3.6 ng/ml for Vmax and km were suitable to 
obtain Css,avg values comparable to previously published data for oral administration 
[48]. The optimisation of the dose and release rates for emtricitabine and tenofovir 
considered not only plasma concentrations but also the intracellular FTC-TP and 
TFV-DP over the reported in vitro IC50 values of 142 fmol/10
6 cells and 150 fmol/106 
cells [134].  
2.2.10. Sensitivity analysis 
Differential sensitivity analysis was performed to identify the key parameters that 
impact the pharmacokinetic profiles of LAI formulations [135]. The sensitivity coef-
ficient (ϕi) indicates the change of plasma concentration values (Y) with respect to a 
unit change in a parameter (X) as shown in equation 1 [135].  
∅𝑖 =
%∆𝑌
%∆𝑋
      (1) 
Analysis was performed with the first monthly IM dose for all the 8 ARVs in 
adults. Sensitivity was analysed using the provided inbuilt feature of Simbiology at 
user-defined values without normalisation in the computation. Six parameters – 
blood-to-plasma ratio, cardiac output, clearance, weight, protein binding, and release 
rate were analysed against plasma concentration of the drug. Each parameter was var-
ied 20 % from its mean value and 100 simulations were run while keeping the rest of 
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the parameters constant and the analysis was performed. Sensitivity greater than 0.1 
was considered to have a substantial effect on the drug exposure over time. 
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Table 2.2 Physicochemical properties, in vitro and population pharmacokinetic data of ARVs  
Drug Properties 
 Atazanavir Dolutegravir Efavirenz Emtricitabine Etravirine Raltegravir Rilpivirine Tenofovir 
Molecular 
weight 
704 419 316 247 435 444 366 287 
log Po:w 3.17 2.20 4.60 -0.43 5.20 0.58 4.32 1.25 
Protein binding 86.0 % 99.3 % 99.0 % 4.0 % 99.9 % 83.0 % 99.7 % 0.7 % 
pKa 7.4 8.3 10.2 2.65 3.75 6.67 3.26 3.75 
R 0.75 [127] 0.535 [136] 0.74 [114] 1.0 [137] 0.7 [138] 0.6 [54] 0.67 [139] b1 
PSA (Å2) - - 38.33 - 120.64 - - - 
HBD - - 1 - 3 - - - 
Papp (10-6 cm/s) - - 2.5 [114] - - 6.6 [54] 12 [139] - 
ka (h
-1) 1.5 [127] 1.63 ± 1.03 [140]  - 1.0 [141] - - - 1.03 [47]  
F  68 % - - 93 % - - - 20 % 
Vd (L/kg) 1.2 [127] 
- 3.6 1.4 ± 0.3 a6.03 0.6 - 0.813 [142] 
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Metabolism 
 Atazanavir Dolutegravir Efavirenz Emtricitabine Etravirine Raltegravir Rilpivirine Tenofovir 
CL/F (L/h) 
a12.6(10.5-15.4) 
[143]  
1 (15 %) [144] - - - 4.62 [58] - - 
Renal Clear-
ance (L/h) 
- - - 
12.80 ± 5.34 
[137]  
- 3.6 [54] - 
11.3  ± 6.2 
[145]  
CYP2A6 CLint - - 0.08 [114] - - - - - 
CYP2B6 CLint - - 0.55 [114] - - - - - 
CYP1A2 CLint - - 0.07 [114] - - - - - 
CYP3A4 CLint - 
†3.0 [146] 0.007 [114] - 0.012 [147] - 2.04 [139] - 
M2 CYP3A4 
CLint 
- - - - 
0.00091 
[147] 
- - - 
CYP3A5 CLint - - 0.03 [114] - - - - - 
CYP2C19 CLint - - - - 0.75 [147] - - - 
UGT1A1 CLint  - 
†3.2 [146] - - - ‡12.4 [54] - - 
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CYPs induction  
 Atazanavir Dolutegravir Efavirenz Emtricitabine Etravirine Raltegravir Rilpivirine Tenofovir 
CYP3A4 Indmax - - 6.5 [114] - 2.5 [147] - - - 
CYP2B6 Indmax - - 5.7 [114] - - - - - 
CYP3A4 Ind50 - - 3.9 [114] - - - - - 
CYP2B6 Ind50 - - 0.8 [114] - - - - - 
a An average adult body weight of 70 kg was assumed, b Value was an assumption (as the drug is similar to emtricitabine  and tenofovir 
value was not available in the literature), † The units are in µl/min/mg, ‡ The units are in µl/min/106 hepatocytes; log Po:w – Partition 
coefficient between octanol and water; pKa – logarithmic value of the dissociation constant; R – blood-to-plasma drug ratio; PSA – polar 
surface area; HBD – number of hydrogen bond donors; Papp – drug permeability from apical to basolateral in caco-2 cell monolayer;; Ka 
– absorption coefficient; F – absolute bioavailability; Vd – volume of distribution; CL/F – Apparent oral clearance; Clint – intrinsic clear-
ance (µL/min/pmol); CYP – cytochrome P450; UGT - uridine diphosphate glucuronosyltransferase; M2 – Second metabolite; Indmax – 
induction maximum; Ind50 – 50 % induction; ‘-‘ – data not available/ not applicable  
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Table 2.3a Validation of antiretrovirals at steady state: Clinical vs. Predicted AUC, Cmax and Ctrough 
Drug 
Dose 
(mg) 
AUC (ng×h/ml) Cmax (ng/ml) Ctrough (ng/ml) 
Clinical aPredicted Clinical aPredicted Clinical aPredicted 
Efavirenz 600 OD a57,150 ± 27,300 [148] 65,006 ± 16,383 4,000 ± 1,710 [148] 3,193 ± 699.7 2,380 ± 1,140 [148] 2,298 ± 671.0 
Etravirine 200 BD a3,713 ± 2,069 [149] 3,939 ± 1,249 451.3 ± 232.3 [149] 375.0 ± 106.1 235.9 ± 163.1 [149] 285.4 ± 100.5 
Rilpivirine 25 OD a2,589 ± 868.8 [139] 3,590 ± 1,256 203.8 ± 75.81  [139] 214.1 ± 53.9 89.85 ± 38.07 [139] 95.7 ± 49.5 
Raltegravir 400 BD a7,076 ± 4,071 [150] 9,584 ± 2,160 2,519 ± 1,930  [150] 2,002 ± 378.9 71 ± 50      [150] 54.6 ± 52.1 
Atazanavir 400 OD a29,303 ± 8,263 [151] 24,354 ± 4,307 5,358 ± 1,371 [151] 2,718 ± 392.2 218 ± 191   [151] 326.9 ± 150.0 
Tenofovir 300 OD b3,324 (41.2 %) [142] 4,707 ± 1,004 326 (36.6 %) [142] 580.2 ± 80.6 64.4 (39.4 %) [142] 20.7 ± 17.7 
Emtricitabine 200 OD b10,100 (18 %) [48] 9747 ± 2326 1,720 (16 %) [48] 1,136 ± 236.3 73 (28 %)    [48] 52.5 ± 32.2 
Dolutegravir 50 OD b53,600 (27 %) [144] 63,615 ± 8,802 3,670 (20 %) [144] 3,474 ± 519.6 1,110 (46 %) [144] 1,867 ± 309.0 
a Arithmetic Mean ± S.D.,  b Geometric Mean (% CV – coefficient of variation expressed as a percentage), AUC – area under the concen-
tration-time curve, Cmax – maximum plasma concentration, Ctrough – trough plasma concentration, OD – once daily, BD – twice daily.  
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Table 2.3b Validation of antiretrovirals at steady state: Percentage difference between 
clinical vs. predicted AUC, Cmax and Ctrough 
Drug AUC Cmax Ctrough 
Efavirenz 13.7% -20.2% -3.4% 
Etravirine 6.1% -16.9% 21.0% 
Rilpivirine 38.7% 5.1% 6.5% 
Raltegravir 35.4% -20.5% -23.1% 
Atazanavir -16.9% -49.3% 50.0% 
Tenofovir 41.6% 78.0% -67.9% 
Emtricitabine -3.5% -34.0% -28.1% 
Dolutegravir 18.7% -5.3% 68.2% 
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2.3. Results 
The validation was conducted by comparing the mean simulated Ctrough, Cmax and 
AUC with the available clinical data for oral administration and also for an existing 
LA IM formulation of rilpivirine (600 mg; 100 mg/ml) (shown in Figure 2.1). For 
emtricitabine and tenofovir, the Css,avg of FTC-TP and TFV-DP were compared with 
clinical data [48]. Although the commonly agreeable limits of variability for valida-
tion is 2-fold from the mean value, we used a more stringent value of 0.5-fold to 
enhance the accuracy of the predictions [152]. 
 
Figure 2.1 Validation of the physiologically based pharmacokinetic strategy against 
clinical data for an existing rilpivirine long-acting nanoformulation (600 mg; 100 
mg/ml) [87]  
For IM formulations, multiple dose and release rate combinations were simulated 
to obtain mean predicted Ctrough greater than the defined cut-off. For tenofovir and 
emtricitabine, the dose and release rates for IM injection were optimised such that the 
plasma concentrations were over the IC90 value and also the Css,avg were over the in-
tracellular IC50. 
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A summary of the predicted AUC, Cmax and Ctrough for eight ARVs following op-
timal IM injection is shown in Table 2.4. 
2.3.1. Rilpivirine 
The validation of the PBPK model for rilpivirine was done using available oral 
clinical data. The simulated mean AUC, Cmax and Ctrough values  deviated +38.7 %, 
+5.1 % and +6.7 %, respectively from the clinical data [139]. The PBPK model was 
additionally validated against an existing LA IM formulation of rilpivirine (600 mg; 
100 mg/mL) [87]. The release rate from the IM depot was predicted after matching 
the model to the clinical pharmacokinetic data. The drug release followed dose-de-
pendent first-order kinetics and the release rate was predicted to be between 0.0009 
and 0.0012 h-1 (Figure 2.1). The  mean values for AUC were 84.0 ng×h/ml vs. 83.38 
± 33.34 ng×h/ml, Cmax 96.7 ng/ml vs. 86.73 ± 30.51 ng/ml
 and Ctrough 15.7 vs. 11.81 
± 6.3 ng/ml  for clinical versus simulated data. After the validation step with both oral 
and LA IM formulations, the optimal dose and release rates of both weekly and 
monthly injection regimens of rilpivirine were identified such that the plasma con-
centration is over the PAIC95 value of 20.3 ng/ml [153]. A weekly dose of 60 mg with 
a release rate of 0.02 h-1 and a monthly dose of 250 mg with a release rate of 0.002 h-
1 were predicted to maintain the plasma concentrations above the target cut-off. 
2.3.2. Atazanavir 
The validation at steady-state for the oral administration of unboosted atazanavir 
resulted in mean predicted AUC, Cmax and Ctrough values which were -16.9 %, -49.3 
% and +50.0 % of those observed clinically [151]. An IM dose of 1500 mg atazanavir 
was predicted to result in plasma concentrations after 30 days below the PAIC95 (60 
ng/ml) and was therefore deemed unsuitable for monthly injection. An IM weekly 
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dose of 400 mg however was predicted to achieve mean concentrations in excess of 
the PAIC95 with a release rate of 0.009 h
-1 [154].  
2.3.3. Dolutegravir 
The predicted variation from the clinical values for mean AUC, Cmax and Ctrough 
in the validation of oral administration of dolutegravir were +18.7 %, -5.3 % and 
+68.2 %, respectively [144]. Considering the PAIC95 value of 64 ng/ml as the target 
concentration, the simulated IM administration requires an estimated weekly dose of 
20 mg with a release rate of 0.006 h-1 and a monthly dose of 105 mg with a release 
rate of 0.002 h-1 [155]. 
2.3.4. Emtricitabine 
The predicted variation from the clinical values in mean AUC, Cmax and Ctrough for 
oral emtricitabine were -3.5 %, -34.0 % and -28.1 %, respectively [137] and the sim-
ulated mean Css,avg of intracellular FTC-TP has a deviation of +10.9 % from the clin-
ical value (Table 2.5). The IC90 value of 50.2 ng/ml and intracellular IC50 of 127 
fmol/106 cells were considered as target concentrations [48, 156]. The simulated IM 
injection required a dose of 375 mg with a release rate of 0.009 h-1 for a weekly ad-
ministration and 1500 mg with a release rate of 0.0015 h-1 for a monthly administra-
tion [48].  
2.3.5. Efavirenz 
The validated PBPK model yielded AUC, Cmax and Ctrough values, which were 
+13.7 %, -20.2 % and -3.4 % compared to the clinical values [148]. In order to obtain 
plasma concentrations above the PAIC95 value of 126 ng/ml, a weekly IM dose of 200 
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mg (release rate - 0.015 h-1) and monthly dose of 800 mg (release rate - 0.007 h-1) 
were required [154].  
2.3.6. Etravirine 
The validated PBPK model with oral administration of etravirine resulted in mean 
AUC, Cmax and Ctrough values which were +6.1 %, -16.9 % and +21.0 % compared to 
the clinical values [149]. The IM predictions indicate that etravirine may be suitable 
for weekly administration with a dose of 700 mg and release rate of 0.015 h-1 but not 
for monthly administration as the drug concentrations fall below the PAIC95 value 
even for an IM dose of 1500 mg [154]. 
2.3.7. Raltegravir 
The predicted mean AUC, Cmax and Ctrough of orally administered raltegravir were 
+35.4 %, -25.0 % and -30.3 % compared to the clinical values, respectively [150]. To 
maintain the plasma concentrations above the IC95 value (15 ng/ml), the prediction 
suggested a dose of 200 mg (release rate – 0.005 h-1) and 800 mg (release rate – 0.002 
h-1) may enable weekly and monthly IM administration of raltegravir, respectively 
[157].  
2.3.8. Tenofovir disoproxil fumarate (TDF) 
The validated PBPK model for TDF predicted mean AUC, Cmax and Ctrough which 
were +41.6 %, +78.0 %, -67.9 % compared to the clinical data, respectively [142]. 
The deviation of the intracellular Css,avg was +4.2 % compared to the clinical value 
(Table 2.5). 200 mg TDF with a release rate of 0.008 h-1 was predicted to provide a 
sufficient exposure following weekly IM injection and 1300 mg with a release rate of 
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0.002 h-1 was an adequate dose for a monthly IM administration, maintaining mean 
plasma concentrations above the IC90 and intracellular TFV-DP above the IC50 [134]. 
 
Figure 2.2 Pharmacokinetics of monthly administration of antiretrovirals over a pe-
riod of 6 months. a) Dolutegravir, b) Efavirenz, c) Emtricitabine, d) Raltegravir, e) 
Rilpivirine and f) Tenofovir.  Mean, Mean ± S.D.,  
PAIC95/IC95 
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Table 2.4 Prediction of the dose and release rate of single intramuscular injection of antiretrovirals (Mean ± S.D.) 
Drug 
Intramuscular 
Dose (mg) 
Release 
rate (h-1) 
Weekly/ 
Monthly 
AUC 
(µg.h/ml) 
 (Mean ± 
SD)† 
Cmax 
(ng/ml)            
 (Mean ± SD)† 
Ctrough 
(ng/ml)                  
(Mean ± SD)† 
Target  
concentration 
(ng/ml) 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
Emtricitabine 
1,500 0.0015 Monthly 43.1 ± 15.4 94.2 ± 32.5 51.2 ± 41.3 
50.2 [48] (IC90) 
375 0.009 Weekly 20.5 ± 8.9 199.4 ± 76.1 55.6 ± 26.4 
Tenofovir 
1,300 0.002 Monthly 52.2 ± 15.4 99.2 ± 28.6 43.8 ± 17.2 
18 [158] (IC90) 
200 0.008 Weekly 16.6 ± 7.1 155.6 ± 58.5 49.1 ±23.0 
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
Efavirenz 
800 0.007 Monthly 333.9 ± 99.3 850.4 ± 194.6 140.0 ± 50.8 126 [154] (PAIC95)
 
[154] [154] 200 0.015 Weekly 73.2 ± 22.1 546.5 ± 139.5 273.3 ± 81.8 
Etravirine 700 0.015 Weekly 43.4 ± 12.3 359.3 ± 80.7 126.1 ± 60.7 116 [154] (PAIC95) 
Rilpivirine* 
250 0.002 Monthly 32.9 ± 14.7 75.4 ± 30.1 22.6 ± 8.2 
20.3[153] (PAIC95) 
60 0.015 Weekly 10.8 ± 4.8 97.4 ± 33.3 26.1 ± 18.7 
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Integrase Inhibitors (IIs) 
Dolutegravir 
105 0.002 Monthly 95.6 ± 8.5 212.1 ± 18.1 65.7 ± 7.1 
64 [155] (PAIC95) 
20 0.006 Weekly 24.2 ± 2.8 169.5 ± 18.1 101.7 ± 14.8 
Raltegravir 
800 0.002 Monthly 26.1 ± 5.2 66.9 ± 13.1 15.7 ± 2.8 
15 [157] (IC95) 
200 0.005 Weekly 8.23 ± 1.47 69.4 ± 12.1 30.1 ± 5.4 
Protease Inhibitors (PIs) 
Atazanavir 400 0.009 Weekly 38.9 ± 8.3 334.3 ± 70.7 114.8 ± 25.4 60 [154] (PAIC95) 
* Note that this dose is not for the existing rilpivirine formulation; †Arithmetic Mean and standard deviation; AUC – area under the 
concentration-time curve, Cmax – maximum plasma concentration, Ctrough – trough plasma concentration, IC90 – 90 % inhibitory concen-
tration, PAIC95 – 95 % protein binding adjusted inhibitory concentration 
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Table 2.5 Validation and prediction of intracellular concentration of emtricitabine triphosphate and tenofovir diphosphate 
Css,avg – Average steady state concentration, Ctrough -  trough concentration at the end of the duration, Cmax – maximum concentration, IC50  
- 50 % inhibitory concentration
Active Drug 
Intracellular Css,avg  (fmol/106 cells) Weekly/ 
Monthly 
Intramuscular Prediction (fmol/106 cells) In vitro IC50 
(fmol/106 cells) Clinical Simulated Intracellular Ctrough Intracellular Cmax 
Emtricitabine 
triphosphate 
1124.4 ± 592.1 [48] 1,154 ± 456 
Monthly 163.0 ± 124.6 228.2 ± 106.1 
127 [156] 
Weekly 270.0 ± 130.0 431.8 ± 198.4 
Tenofovir di-
phosphate 
150.7 ± 92.9 [49] 156.5 ± 59.5 
Monthly 154.2 ± 46.5 164.6 ± 49.3 
150 [134] 
Weekly 163.0 ± 59.0 174.9 ± 62.8 
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2.3.9. Sensitivity analysis 
The mean differential sensitivity analyses of 100 runs performed for the eight ARVs is 
presented in Figure 2.3. Atazanavir and dolutegravir consist of two charts each as shown in 
Figure 2.3a due to high sensitivity observed for two parameters. 
Atazanavir was highly sensitive to the weight of the individual compared to unbound frac-
tion (fu), blood-to-plasma ratio (R), IM release rate (Kim) and cardiac output (CO) and not sen-
sitive to systemic clearance (CL). Weight, fu and CO showed a positive relationship against 
plasma concentration in the initial days indicating an increase in plasma concentration with 
increase in these parameters than in the subsequent days with a negative correlation. A delayed 
pattern with lower sensitivity could be observed for R, however Kim showed a negative corre-
lation throughout imposing a negative effect on the plasma concentration as this parameter 
increases. 
Dolutegravir plasma concentration is highly sensitive to Kim with a positive correlation. 
Change in fu does not have any effect on the plasma concentration. The rest of the parameters 
have a low sensitivity negative relationship with a decrease in plasma concentration if there is 
an increase in these parameters.  
Efavirenz drug specific parameters fu, Kim, R and weight of the individual were observed 
to have a negative correlation against plasma concentration throughout the analysis indicating 
a decrease in the exposure as these parameters increase. However, systemic clearance and car-
diac output doesn’t seem to have any effect on the plasma concentration. 
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Emtricitabine pharmacokinetic curve has a negative correlation with all the six parameters. 
However the sensitivity is below 0.1 for all the parameters, which implies that they do not have 
any substantial effect on the plasma concentration curve. 
Weight of the individual is highly sensitive and has a negative correlation against plasma 
concentration of etravirine. Rest of the parameters lie between ± 0.03, indicating a minimal 
effect. Clearance was observed to have an initial positive correlation and changes to a negative 
correlation as time progresses, but the rest of the parameters show a negative correlation. 
Raltegravir, rilpivirine and tenofovir have a minimal effect on their respective plasma con-
centrations with a change in these six parameters since the sensitivity against this parameters 
lies within a mere ± 0.004 throughout the dosing interval. 
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Figure 2.3a Sensitivity analysis of six different parameters against plasma concentration for a single IM dose of dolutegravir and ataza-
navir  
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Figure 2.3b Sensitivity analysis of six different parameters against plasma concentration for a single IM dose of efavirenz, etravirine, 
emtricitabine and raltegravir 
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Figure 2.3c Sensitivity analysis of six different parameters against plasma concentration for a single IM dose of rilpivirine and tenofovir 
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2.4. Discussion 
Imperfect adherence to daily oral ARV formulations continues to hinder the effi-
cacy of HIV therapy and PrEP. Alternative administration strategies are beginning to 
emerge that provide opportunities for once monthly or even less frequent administra-
tion. A greater understanding of formulation characteristics is required to predict dose 
and release rates that provide adequate pharmacokinetic exposure relative to potency. 
This information will facilitate development of newer LAI ARV formulations. 
In this study, PBPK modelling was used to predict the pharmacokinetics of ARVs 
following IM injection. The PBPK models were initially validated for eight orally 
administered ARVs against available clinical data for oral formulations. Subse-
quently, IM administration was simulated by adding an additional compartment to the 
model to represent the IM depot. For this, a first-order kinetics constant was applied 
to represent the diffusion of ARVs from the depot to the surrounding blood capillaries 
(as shown in Chapter 1 Figure 1.7). This approach was validated comparing simulated 
pharmacokinetics of rilpivirine following IM injection versus available clinical data 
for the LAI formulation. The primary objective of this study was to identify whether 
drug-specific doses and release rates from the depot predicted compatibility for IM 
administration. To obtain the suppression of the viral replication, ARV Ctrough should 
reach and be maintained at concentrations above the susceptibility of the virus to that 
drug. Where possible, dose and release rate were optimised such that the ARV Ctrough 
remained above previously identified target values. Target concentrations were iden-
tified as equal to PAIC95 which represent the ARV concentration that can inhibit 95 
% of the virus replication in vitro. Since emtricitabine and tenofovir are characterised 
by very low protein binding (< 4 % and < 0.7 % respectively) IC90 values were con-
sidered (IC95 data not available). The intracellular concentrations of FTC-TP and 
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TFV-DP were also used as target concentrations in the optimisation of IM dose and 
release rates for emtricitabine and tenofovir. Although the PAIC95 represents a ra-
tional pharmacodynamic cut-off and has been discussed extensively elsewhere, some 
ARVs do not exert a good relationship between trough concentrations and virologic 
efficacy [154]. In certain cases clinical studies have suggested that the minimum ef-
fective concentrations for therapy might be higher than the in vitro IC95. 
The validation of PBPK models is essential to identify the correct parameters for 
an accurate simulation of each ARV. Since evidence suggests that dissolved molecule 
rather than nanoparticle predominates systemically after IM administration of SDNs 
[79], the volume of distribution, metabolism and elimination were fixed irrespective 
of the route of administration. As such, it should be noted that the presented data are 
only applicable when this is assumed to be the case, and these models cannot be ap-
plied to technologies that change these parameters (e.g. nanocarrier systems such as 
nanoemulsions or polymeric nanoparticles). In these cases, part of the formulation 
should be considered as intravenous administration, if the carrier systems reach the 
blood stream intact. Depending on the carrier stability in the aqueous environment, 
the nanoparticles can either provide instant or prolonged release thus changing the 
drug distribution kinetics. Additionally, particles less than 5 nm are eliminated by 
kidneys, altering the elimination pattern [159]. Each model prediction was carried out 
at steady-state to better represent the long-term ARV pharmacokinetics and relevant 
clinical scenarios. The model was considered validated if the mean AUC of the sim-
ulation for each ARV was within ± 50 % compared to clinically reported values. The 
simulated values from all the included PBPK models were in agreement with availa-
ble clinical data and were therefore used for prediction of pharmacokinetics after IM 
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administration. The simulations were carried out for weekly and monthly administra-
tion and the maximum injectable dose was set to 1.5 g since doses above this have 
not previously been practical for IM formulations [99]. Table 2.4 illustrates that the 
release rate was inversely proportional to the dosage, and a slower release rate was 
required for monthly administration.  
Our PBPK models predicted that two NRTIs, emtricitabine and tenofovir, may be 
suitable for weekly or monthly administration. Importantly, emtricitabine and tenofo-
vir are widely used in HIV treatment and prevention, and LAI formulations of these 
agents would make possible multi-drug regimens that match current clinical para-
digms for therapy. These agents also represent good candidates for monthly PrEP due 
to their excellent safety and efficacy profiles. Tenofovir alone, or tenofovir combined 
with emtricitabine, have already been shown to provide good protection against HIV 
infection in individuals at high risk of infection [160]. 
Considering NNRTIs, efavirenz and rilpivirine were both predicted to be suitable 
for monthly administration. Both have long half-lives, which are favourable for de-
velopment of LAI agents. The high systemic clearance of etravirine limits the possi-
bility of a monthly administration format when a dose limit of 1.5 mg is applied. 
Conversely, both integrase inhibitors, dolutegravir and raltegravir, were predicted to 
be suitable for monthly administration. A low dose of 105 mg was predicted to be 
sufficient for monthly administration of dolutegravir if a formulation with optimised 
release rate can be developed. It should be noted that cabotegravir is chemically 
closely related to dolutegravir, and development of a dolutegravir LAI formulation 
may therefore not be warranted. Our simulation indicated that raltegravir could po-
tentially be developed as a monthly IM injection with a dose of 800 mg. The optimised 
dose and release rate for unboosted atazanavir predicted feasibility of an injectable 
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weekly option at 600 mg, but doses higher than 1500 mg would be required for 
monthly administration.  
The optimisation of LAI strategies should be based on a rational analysis of sev-
eral pharmacokinetic factors. For many agents, it is likely that the pharmacokinetic 
variability after IM administration will be reduced compared to oral formulations, due 
to the lower complexity of the absorption process and avoidance of intestinal trans-
porters and first-pass metabolism. However, additional complexities with the accu-
mulation of macrophages, formation of granuloma at the injection site could arise 
which should be investigated further [79]. Therapeutic plasma concentrations were 
predicted to be achieved in approximately eight hours for emtricitabine and tenofovir, 
and ~24 h for the remaining ARVs after a single IM injection (as shown in Figure 
2.2). Since a day is needed to achieve therapeutic plasma concentrations for the other 
ARVs, a loading oral dose equivalent to the daily regimen may be necessary. This 
could represent a minor risk for the development of drug resistance and therapeutic 
failure, but PBPK modelling may help to inform the ongoing debate regarding some 
aspects of the need for an oral lead-in with the same drugs. The co-administration of 
multiple injectable ARVs is possible, but a rational selection of concomitant agents is 
needed to avoid drug-drug interactions. Studies to validate the utility of co-admin-
istration of the two existing LAI drugs, rilpivirine and cabotegravir, are underway 
[161].  
The PBPK approach is characterised by some intrinsic limitations due to existing 
knowledge gaps and the complexity of biological processes underpinning drug distri-
bution. For example, muscle tissues are well connected to the lymphatic circulation, 
and drugs with high lipophilicity tend to diffuse through lymphatics rather than blood 
vessels [124]. Consequently, higher accumulation of ARVs in lymph nodes might be 
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possible, but there is a paucity of clinical data in this area for available LAI formula-
tions. Similarly, efflux and influx transporters are of clear importance to intestinal 
absorption, distribution and clearance of drugs, but there is currently very little data 
on the activity of the transporters (or metabolic enzymes) that are expressed at the 
depot sites. Gender has been correlated with changes in plasma exposure in a recent 
clinical study of rilpivirine LAI. [162]. Although it has been suggested that several 
factors can define this, the physiological and anatomical mechanisms characterising 
the differences between genders have not been fully elucidated and consequently have 
not been included in our simulations. 
Although the doses and release rates identified through these simulations set tar-
gets for optimal nanoparticle design, it is important to underscore that the technolog-
ical challenges in achieving these formulation characteristics are not addressed in this 
work. Long-term stability of the ARVs in the interstitial fluid present at the depot site 
is another important consideration. Since SDN strategies do not involve the use of a 
carrier with stable size and dissolution rates over time, the nanoparticle properties are 
likely to change over the dosing interval. Since this will alter the surface to mass ratio, 
an effect on ARV release kinetics with downstream effect on the overall pharmaco-
kinetics cannot be ruled out. It may also be important to consider other SDN compo-
nents, such as polymers and surfactants, which will also be gradually released over 
time [163]. The use of LAI ARVs might determine specific complications at the site 
of injection as described for other treatments; additionally given the prolonged sys-
temic exposition of LAI ARV and the inability to interrupt the drug in the event of 
side effects, a period of oral induction might be considered before initiating LAI. For 
patients discontinuing the LAI ARV therapy, an oral administration strategy should 
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be hypothesised in order to prevent resistance development due to the diminishing 
plasma concentrations [121].
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3.1. Introduction 
The dose adjustments for paediatric patients is commonly derived by scaling down 
adult dosing. Scarcity in volunteer enrolment and associated ethical issues can repre-
sent a barrier for clinical studies in paediatric patients as well as other special popu-
lation of patients [164]. Studies have shown that dose adjustments in paediatric pa-
tients can lead to inadequate or excessive exposure resulting in sub-optimal therapeu-
tic effect and increased adverse effects [165, 166]. Currently, the majority of the dos-
ing strategies for children are based on empirical scaling from adult doses based on 
weight or body surface area (BSA).  
Dose optimisation is particularly critical in the paediatric population because the 
patient physiological and anatomical characteristics and the maturation of relevant 
enzymes are characterised by non-linear changes over time.  Chloramphenicol, an 
antibiotic used in the 1950s for various infections increased mortality rate especially 
in neonates and infants who were prescribed a dose by scaling down adult dose by 
weight [167]. This study along with the investigation of cytochrome P450 ontogeny 
[168] and growth charts by CDC [169] indicated that child growth is not linear and 
could put the paediatric patients at risk of receiving sub-therapeutic or too high doses 
during chronic drug usage [170].  
Pharmacokinetic modelling has been increasingly used to support the optimisation 
of dosing in special populations [171]. Recent regulatory changes in U.S. and Europe 
are supporting the integration of clinical studies for paediatric patients to rationalise 
the selection of suitable dosing strategies [164, 172]. Unfortunately, ethical con-
straints hamper the clinical investigations, consequently the integration of predictive 
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computational tools can support a more rational identification of therapeutic doses for 
paediatric patients.  
Traditional allometric scaling from adults to paediatrics using age and body sur-
face area does not take into account the organ growth and protein expression changes 
which can have a major effect on ADME processes and pharmacokinetics. PBPK 
modelling may be successfully used to predict pharmacokinetics in paediatric patients 
[172]. This modelling technique can integrate the current knowledge of the physio-
logical and anatomical changes in different age groups in a mathematical mechanistic 
description of ADME [172, 173]. PBPK modelling could be used to inform the opti-
mal doses without clinical intervention, informing a rational design of prospective 
clinical studies.  
The aim of this chapter was to validate the anatomy and physiology of the paedi-
atric model for different age groups between 2-18 years. To improve the confidence 
of the model, it has also been validated against available clinical data in paediatric 
population aged between 3-18 years for intravenous lorazepam and an intramuscular 
administration of ceforanide.   
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3.2. Methods 
Anatomy and physiology of children between the ages 2-7 and 7-18 years were 
validated. The assumptions of the PBPK model were mentioned in section 2.2. The 
PBPK model was constructed using Simbiology v.4.3.1, a product of Matlab v.8.2 
(MathWorks, Natick, MA, USA 2013). The simulated pharmacokinetics were vali-
dated against published clinical data for lorazepam, an anti-anxiety agent and cefo-
ranide, an anti-bacterial agent as model drugs [174, 175]. 
3.2.1. Anatomy 
The weight and body mass index of the individuals were defined using Centers 
for Disease Control and Prevention (CDC) growth charts. The charts were digitalised 
using Plot Digitizer Tool (plotdigitizer.sourceforge.net) and polynomial trend line 
feature in Microsoft Excel was used to obtain the relation between age and other pa-
rameters [176].  Using these defined parameters as reference, height and body surface 
area [177] were calculated using allometric equations from the literature (Table 3.1). 
3.2.2. Tissue and organ weights 
The tissue and organ weights were computed using allometric equations. All the 
organ weights were validated against published data for both male and female popu-
lations at different age groups [178]. Summary of the equations used and their refer-
ences are shown in Table 3.2a, b. 
3.2.3. Blood flow 
The cardiac output for different age groups was obtained from literature sources. 
The blood flow rates of various organs and tissues were adjusted as the percentage of 
cardiac output such that they match the clinical values [179]. The sum of blood flow 
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passing through the gut, pancreas, spleen and stomach was considered as the portal 
vein blood flow rate for PBPK models. The percentage of blood flow passing through 
each organ or tissue was adjusted according to the data in the literature (Table 3.3) 
[179]. 
3.2.4. Validation of anatomy and physiology 
Validation was performed for ages 2, 5, 10 and 15 years of children and adoles-
cents. The paediatric characteristics, individual tissue and organ weights and blood 
flows were validated against available literature data [178, 179]. Simulations were 
performed for a population (100 individuals) by including standard deviation from 
the literature or ± 20 % was assumed in each age group if data was not available and 
the mean value was validated against literature data for both male and female groups.  
3.2.5. Pharmacokinetic validation  
To improve the confidence of the constructed models, it was also validated against 
in vivo pharmacokinetic data for lorazepam, an anti-anxiety drug and an anti-bacterial 
agent, ceforanide [174, 175]. These drug was chosen due to the availability of physi-
cochemical and pharmacokinetic data in paediatric individuals required for the con-
struction and validation of the PBPK model. Dose of 0.05 mg/kg to a maximum of 2 
mg was administered intravenously for lorazepam and a single intramuscular 20 
mg/kg dose of ceforanide were simulated for 500 male individuals in each age group 
(3-7 and 7-18 years). Maximum concentration (Cmax), area under the curve (AUC) 
and volume of distribution (Vd) were compared against clinical data [174]. 
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3.2.6. ADME characteristics 
The equations describing the ADME processes defining PK were derived from 
previously published PBPK models (see Chapter 2, section 2) [119, 120]. The physi-
cochemical and intrinsic clearance values of lorazepam were obtained from Maharaj 
et al. [180], plasma clearance of ceforanide from Dajani et al. [175] and the extrapo-
lation to systemic clearance and the distribution of drug to different organs and tissues 
was computed using previously published equations [120, 133]. 
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Table 3.1 Equations describing the anatomical characteristic features for paediatrics (2-18 years)  
  Sex 2-7 years 7-18 years 
BMI 
(kg/m2) 
Male 
(-2E-06*(Age*12)^3+0.0009*(Age*12)^2-0.096*(Age*12)+18.41) ± (4E-
09*(Age*12)^4-3E-06*(Age*12)^3+0.0006*(Age*12)^2-0.0421*(Age*12)+1.9366) [176] 
(0.004*Age^2+0.5348*Age+10.92) 
± 3 [176] 
Female 
(-2E-06*Age^3 + 0.0011*Age^2 - 0.1058*Age + 18.249)±(7E-09*Age^4 - 4E-06*Age^3 
+ 0.0009*Age^2 - 0.0579*Age + 2.2788) [176] 
(-0.0204*Age^2 + 1.1067*Age + 
7.7386) ± 3 [176] 
Weight (kg) 
Male 
(-1E-07*(Age*12)^4+4E-05*(Age*12)^3-0.0052*(Age*12)^2+0.4118*(Age*12)+4.6681) 
± (3E-10*(Age*12)^5-2E-07*(Age*12)^4+5E-05*(Age*12)^3-
0.0051*(Age*12)^2+0.2379*(Age*12)-2.3971) [176] 
(-0.0419*Age^3+1.684*Age^2-
17.334*Age+78.678) ± 4.5 [176] 
Female 
(-9E-09Age4 - 6E-06Age3 + 0.003Age2 - 0.1028Age + 13.926) ± (4E-10Age5 - 3E-
07Age4 + 5E-05Age3 - 0.0045Age2 + 0.1886Age - 1.4623) [176] 
(-0.239x2 + 9.6465x - 39.288) ± 4.5 
[176] 
BSA (m2) Both 0.0235*((Height*100)^0.42246)*(Weight^0.51456) [177] 
Height (m) Both sqrt(Weight/BMI) 
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Table 3.2 a) Allometric equations describing organ and tissue weights (kg) for male children between 2-18 years 
  2-7 years 7-18 years 
Adipose 0.534*Weight-1.59*Age+3.03 [181] (1.51*BMI-0.7*Age-3.6+1.4)*Weight/100 ± 0.041 [129] 
Blood 
(-0.0623*(Age^5)+2.4425*(Age^4)-31.37*(Age^3) 
+149.98*(Age^2) +31.305*Age+393.7)/1000 ± 0.15 [182] 
(3.33*BSA-0.81) ± 0.1 [129] 
Bones 
(-0.0306*(Age^5)+0.5222*(Age^4)+9.7109*(Age^3)-
197.97*(Age^2)+1089.7*Age+546.6)/1000 ± 0.15 [182] 
exp(0.0689+2.67*log(Height)) ± 0.166 [181] 
Brain (0.405*exp(-Age/629)*(3.68-2.68*exp(-Age/0.89)) ± 0.084 [181] 
Glands (0.001*(Age^5)-0.0483*(Age^4)+0.8335*(Age^3)-6.6516*(Age^2)+27.512*Age+13.9 ± 0.015)/1000 [182] 
Gonads (3.3+53*(1-abs(exp((-Age/17.5)^5.4)))/1000 ± exp(0.049) [129] 
Heart (41.70+0.022*Age*365  ± 25)/1000 [183] 
Intestines (-4.7817e-2*(Age^4)+1.925*(Age^3)-22.382*(Age^2)+107.09*Age+51.125)/1000 ± 0.05 [182] 
Kidneys (35.29+0.015*Age*365+34.14+0.015*Age*365)/1000 ± 2.5 [183] 
Liver (271.58+0.163*Age*365 ± 25)/1000 [183] 
Lungs (41.31+0.039*Age*365+36.92+0.037*Age*365 ± 5)/1000 [183] 
Muscle 0.93*Weight-(Sum of organ weights) [129] 
Remaining exp(-0.072+1.95*log(Height) ± 0.049) [129] 
Skin exp(1.64*BSA-1.93) ± 0.049 [129] 
(-0.0992*(Age^4)+4.2762*(Age^3)-62.165*(Age^2)+437.78*Age+203.2)/1000 
± 0.2*(-0.0992*(Age^4)+4.2762*(Age^3)-
62.165*(Age^2)+437.78*Age+203.2)/1000 [184] 
Spleen (18.42+0.018*Age*365 ± 2.5)/1000 [183] 
Stomach exp(-3.266+2.45*log(Height) ± 0.0965) [129] 
Thymus (14*((7.1-6.1*exp(-Age/11.9))*((0.14+0.86*exp(-Age/10.3))))/1000 ± 0.049 [129] 
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b) Allometric equations describing organ and tissue weights (kg) for female children between 2-18 years 
  2-7 years 7-18 years 
Adipose 0.642*Weight-0.12*Height-0.606*Age+8.98 [181] (1.51*BMI-0.7*Age+1.4)*Weight/100 ± 0.041 [129] 
Blood 
(0.0018*(Age^5)+0.0959*(Age^4)-4.4055*(Age^3)+ 
44.442*(Age^2)+82.808*Age+292.26)/1000 ± 0.15 [182] 
(2.66*BSA-0.46) ± 0.1 [129] 
Bones 
(-2.831e-3*(Age^5)-0.18184*(Age^4)+10.685*(Age^3)-
142.88*(Age^2)+782.05*Age+609.64)/1000 ± 0.15 [182] 
exp(0.0689+2.67*log(Height)) ± 0.166 [181] 
Brain (0.373*exp(-Age/629)*(3.68-2.68*exp(-Age/0.89)) ± 0.084 [181] 
Glands (0.001*(Age^5)-0.0483*(Age^4)+0.8335*(Age^3)-6.6516*(Age^2)+27.512*Age+13.9 ± 0.015)/1000 [182] 
Gonads (3.3+90*(1-abs(exp((-Age/16.8)^6.7)))/1000 ± exp(0.049) [129] 
Heart (41.70+0.022*Age*365  ± 25)/1000 [183] 
Intestines (-0.0513*(Age^4)+2.0352*(Age^3)-23.478*(Age^2)+110.61*Age+49.229)/1000 ± 0.05 [182] 
Kidneys (35.29+0.015*Age*365+34.14+0.015*Age*365)/1000 ± 2.5 [183] 
Liver (271.58+0.163*Age*365 ± 25)/1000 [183] 
Lungs (41.31+0.039*Age*365+36.92+0.037*Age*365 ± 5)/1000 [183] 
Muscle 0.93*Weight-(Sum of organ weights) [129] 
Remaining exp(-0.072+1.95*log(Height) ± 0.049) [129] 
Skin exp(1.64*BSA-1.93) ± 0.049 [129] 
(0.00476622*(Age^5)-0.27924*(Age^4)+6.3444*(Age^3)-
70.113*(Age^2)+429.85*Age+252.06)/1000 ± 0.20*(0.00476622*(Age^5)-
0.27924*(Age^4)+6.3444*(Age^3)-70.113*(Age^2)+429.85*Age+252.06)/1000 
[184] 
Spleen (18.42+0.018*Age*365 ± 2.5)/1000 [183] 
Stomach exp(-3.266+2.45*log(Height) ± 0.0965) [129] 
Thymus (14*((7.1-6.1*exp(-Age/11.9))*((0.14+0.86*exp(-Age/10.3))))/1000 ± 0.049 [129] 
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Table 3.3 Equations for cardiac output and percentages of blood flow rate (L/h) 
to each organ from the cardiac output adjusted according to literature data 
[179].  
 2-7 years 7-18 years 
Cardiac output 
60*(10^(0.8914*log10(Weight)-
0.654)) [185] 
(3.107+(0.012*Weight^1.369))
*60 [186] 
Gender → 
Organ/Tissue ↓ 
Male Female Male Female 
Adipose 0.04 0.05 0.04 0.06 
Bone 0.02 0.02 0.04 0.04 
Brain 0.38 0.38 0.24 0.24 
Gut (Qgu) 0.12 0.13 0.14 0.15 
Hepatic artery 0.08 0.08 0.06 0.07 
Kidneys 0.13 0.11 0.17 0.13 
Lungs 0.02 0.02 0.02 0.02 
Muscle 0.05 0.06 0.12 0.11 
Portal vein (Qpv) Qgu+Qst+Qsp 
Remaining 0.07 0.06 0.08 0.08 
Skin 0.03 0.03 0.04 0.04 
Spleen + Pancreas (Qsp) 0.05 0.05 0.04 0.04 
Stomach (Qst) 0.01 0.01 0.01 0.01 
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Table 3.4 Physicochemical properties, in vitro and population pharmacokinetic 
data of lorazepam and ceforanide 
 Lorazepam Ceforanide 
Molecular weight 321 519 
log Po:w 2.39 [180] -3.7 [188] 
Protein binding (%) 0.93 [187] 80.6 [188] 
pKa 
1.3 (base), 11.5 (acid)  
[180] 
2.55 (acid), 9.14 (base) 
[188] 
R 0.642 [180] †0.1173 
UGT2B7 CLint  0.439 [180] - 
Renal clearance 0.01 [180] - 
Plasma clearance - 72 ± 21 [175] 
 
log Po:w – Partition coefficient between octanol and water; pKa – logarithmic value of 
the dissociation constant; R – blood-to-plasma drug ratio; CLint – intrinsic clearance; 
UGT - uridine diphosphate glucuronosyltransferase (ml/min/g of liver), renal clear-
ance is in ml/min/kg, † the value was computed from the correlation provided by 
Paixão et al. [189] 
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3.3. Results 
The mean simulated values of the anatomy and blood flow rates of children and 
adolescents were compared against literature values [178, 179]. The simulated paedi-
atric characteristic values for BSA, height and weight are in agreement with literature 
data as shown in Table 3.5. Allometric equations from various literature sources de-
scribing the organ and tissues weights and blood flow rates of children and adoles-
cents are in agreement with the published data, shown in Table 3.6 and Table 3.7.  A 
separate ‘remaining’ compartment was created to accommodate the unaccounted 
weight (data not shown) and its corresponding blood flow rate in order to improve the 
model prediction. Since there was no data for age groups other than 2, 5, 10 and 15 
years, anthropometric equations for 2 and 5 years were considered to predict anatomy 
and physiology between the ages 2 and 7 with relative accuracy and precision. Ob-
served growth pattern was slightly different from 7 years onwards therefore different 
equations were used for allometric scaling [176].  Due to large variation in anatomical 
and physiological characteristics among children and adolescents, broader validation 
range i.e. ± 100 % was assumed (less than the conventional two-fold range [152]). 
The mean values from the chosen anthropometric equations were between the as-
sumed ranges from the reported literature values [179] except for the lung weight of 
a 10-year-old child (101.2 %). The mean simulated blood flow rates were ± 50 % 
from the literature value for all the age groups (Table 3.7). 
Simulated lorazepam pharmacokinetics were compared against clinical data as 
shown in Table 3.8. The pharmacokinetics were predicted across all age groups from 
3-17 years and the mean value was compared with clinical data. The Cmax, AUC and 
Vd were +37.5 %, +22.2 % and -14.6 % from clinical values [174]. The simulated 
Cmax (+37.5 %) and AUC (+22.2 %) values are slightly high compared to the mean 
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clinical values (Figure 3.1). Validation of intramuscular ceforanide against clinical 
data had a deviation of +7.4 %, +16.6 % and -8.1 % for Cmax, AUC and Vd respectively 
[175]. In both these cases, the simulated Cmax and AUC values are slightly high which 
can be explained by the low volume of distribution observed (Figure 3.1). . Due to 
unavailability of data, the blood-to-plasma ratio, fraction unbound, intrinsic and renal 
clearance were not altered across age groups.  
 
Figure 3.1 Percentage variation of the mean simulated value against mean clinical 
value of lorazepam and ceforanide 
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Table 3.5 Validation of characteristic features against literature data for different ages (data represented as Male/Female) [178, 
179] 
Years → 2 5 10 15 
Characteristic ↓ Simulated Reference Simulated Reference Simulated Reference Simulated Reference 
BSA (m2) 0.76/0.74 NA 0.91/0.91 0.78/0.78 1.20/1.14 1.12/1.12 1.67/1.49 1.62/1.55 
Height (m) 0.87/0.87 NA 1.09/1.09 1.09/1.09 1.39/1.37 1.38/1.38 1.80/1.53 1.67/1.61 
Weight (kg) 12.7/12.1 12.6/11.9 18.0/17.2 18.7/17.7 31.0/34.0  31.4/32.6 56.0/52.0 56.7/53.7 
 
Table 3.6a Validation of organ weights (kg) against literature data for different ages (Data represented as Male/Female) [178, 
179] 
Years → 2 5 10 15 
Organs ↓ Simulated Reference Simulated Reference Simulated Reference Simulated Reference 
Adipose 3.17/2.91 3.76/3.72 4.68/4.26 5.50/5.50 7.45/9.28 8.60/8.60 11.6/14.2 12.0/18.7 
Bones 0.74/0.74 0.85/0.82 2.49/2.49 2.43/2.43 4.6/4.47 4.50/4.50 8.32/8.32 7.18/7.18 
Brain 1.50/1.50 1.12/1.03 1.48/1.36 1.31/1.31 1.47/1.48 1.40/1.40 1.46/1.34 1.30/1.30 
Glands 0.02/0.02 0/0 0.06/0.06 0.04/0.04 0.07/0.07 0.06/0.06 0.06/0.06 0.10/0.10 
Heart 0.07/0.06 0.07/0.06 0.08/0.08 0.09/0.09 0.12/0.12 0.14/0.14 0.16/0.16 0.22/0.22 
Intestines 0.20/0.19 0.19/0.19 0.24/0.24 0.34/0.34 0.33/0.33 0.58/0.58 0.70/0.69 0.82/0.82 
Kidneys 0.10/0.10 0.09/0.08 0.12/0.12 0.11/0.11 0.18/0.18 0.18/0.18 0.23/0.23 0.24/0.24 
Liver 0.46/0.45 0.48/0.46 0.57/0.57 0.57/0.57 0.87/0.87 0.83/0.83 1.16/1.16 1.30/1.30 
Lungs 0.18/0.18 0.24/0.24 0.22/0.22 0.13/0.13 0.38/0.38 0.21/0.21 0.52/0.52 0.29/0.29 
Muscle 3.37/2.92 2.83/2.83 5.23/4.67 5.60/5.60 7.90/10.42 11.0/11.01 17.5/14.6 17.0/17.0 
Skin 0.52/0.49 0.41/0.39 0.64/0.62 0.57/0.57 1.65/1.65 0.82/0.82 2.19/2.19 1.70/1.70 
Spleen 0.04/0.04 0.07/0.07 0.05/0.05 0.05/0.05 0.08/0.08 0.08/0.08 0.12/0.12 0.13/0.13 
Stomach 0.03/0.03 0.03/0.03 0.05/0.05 0.05/0.05 0.09/0.09 0.09/0.09 0.16/0.11 0.12/0.12 
Thymus 0.02/0.02 NA 0.03/0.03 0.03/0.03 0.03/0.03 0.04/0.04 0.03/0.03 0.03/0.03 
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Table 3.6b Percentage difference in mean organ weights against literature data for different ages and genders [178, 179] 
Years → 2 5 10 15 
Organs ↓ Male Female Male Female Male Female Male Female 
Adipose -15.7 -21.8 -14.9 -22.5 -13.4 7.9 -3.3 -24.1 
Bones -12.9 -9.8 2.5 2.5 2.2 -0.7 15.9 15.9 
Brain 33.9 45.6 13.0 3.8 5.0 5.7 12.3 3.1 
Glands 0.0 0.0 50.0 50.0 16.7 16.7 -40.0 -40.0 
Heart 0.0 0.0 -11.1 -11.1 -14.3 -14.3 -27.3 -27.3 
Intestines 5.3 0.0 -29.4 -29.4 -43.1 -43.1 -14.6 -15.9 
Kidneys 11.1 25.0 9.1 9.1 0.0 0.0 -4.2 -4.2 
Liver -4.2 -2.2 0.0 0.0 4.8 4.8 -10.8 -10.8 
Lungs -25.0 -25.0 69.2 69.2 81.0 81.0 79.3 79.3 
Muscle 19.1 3.2 -6.6 -16.6 -28.2 -5.4 2.9 -14.1 
Skin 26.8 25.6 12.3 8.8 101.2 101.2 28.8 28.8 
Spleen -42.9 -42.9 0.0 0.0 0.0 0.0 -7.7 -7.7 
Stomach 0.0 0.0 0.0 0.0 0.0 0.0 33.3 -8.3 
Thymus - - 0.0 0.0 -25.0 -25.0 0.0 0.0 
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Table 3.7a Validation of organ blood flows (L/h) for different ages against literature values (Data represented as Male/Female) 
[179] 
Years → 2 5 10 15 
Organs ↓ Simulated Reference Simulated Reference Simulated Reference Simulated Reference 
Cardiac Output 129/122 124/114 176.5/132.7 172.8/157.8 269.5/272.5 234/224.4 363.9/347.2 346.2/309 
Adipose 5.1/4.8 5.4/5.8 7.1/8 7.2/7.8 10.8/16.4 10.8/14 14.5/20.8 13.7/25 
Brain 41.0/38.7 54.4/50.1 63.2/32 62.7/57.8 65.6/65.8 55.5/51 46.6/42.6 45/39.9 
Gut 11.3/10.7 13.1/12.4 24.7/19.9 23.5/22.2 37.7/40.9 35.5/35.5 50.9/52 49.7/47.7 
Hepatic Artery 32.1/31.0 43.2/40.8 10.6/9.3 11.3/10.6 16.2/19.1 14.6/15 21.8/24.3 22.7/21.5 
Kidney 11.9/11.3 18.5/13.3 30/17.2 22.6/16.7 45.8/35.5 42.6/30 61.8/45.1 63.2/46.8 
Lungs 8.4/8.0 9.2/8.28 3.5/2.7 3.3/3.1 5.4/5.5 4.1/4.8 7.3/6.9 8.6/7.2 
Muscle 1.6/1.5 2.3/2.3 13.5/14.5 13.1/13.1 31.4/29.8 25.7/25.7 57/45.8 56.2/39.8 
Remaining 5.1/4.8 4.9/4.9 14.1/10.6 11/7.3 21.6/21.8 17.7/18.4 29.1/27.7 37/35 
Skin 3.4/3.2 3.9/3.7 7.1/5.3 5.3/5.1 10.8/10.9 7.7/7.8 14.5/13.9 14.5/12 
Spleen 2.6/2.4 5.0/4.6 7.1/5.3 6.4/6 10.8/10.9 8.9/9.5 14.5/13.9 15.4/13.8 
Stomach 1.2/1.1 1.2/1.1 1.8/1.3 2/1.8 2.7/2.7 3.2/3 3.6/3.5 5/4.5 
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Table 3.7b Percentage difference of mean organ blood flows for different ages against literature values [179] 
Years → 2 5 10 15 
Organs ↓ Male Female Male Female Male Female Male Female 
Cardiac Output 4.0 7.0 2.1 -15.9 15.2 21.4 5.1 12.4 
Adipose -5.6 -17.2 -1.4 2.6 0.0 17.1 5.8 -16.8 
Brain -24.6 -22.8 0.8 -44.6 18.2 29.0 3.6 6.8 
Gut 0.0 0.0 5.1 -10.4 6.2 15.2 2.4 9.0 
Hepatic Artery -25.7 -24.0 -6.2 -12.3 11.0 27.3 -4.0 13.0 
Kidney -35.7 -15.0 32.7 3.0 7.5 18.3 -2.2 -3.6 
Lungs -8.7 -3.4 6.1 -12.9 31.7 14.6 -15.1 -4.2 
Muscle -30.4 -34.8 3.1 10.7 22.2 16.0 1.4 15.1 
Remaining 4.1 -2.0 28.2 45.2 22.0 18.5 -21.4 -20.9 
Skin -12.8 -13.5 34.0 3.9 40.3 39.7 0.0 15.8 
Spleen -48.0 -47.8 10.9 -11.7 21.3 14.7 -5.8 0.7 
Stomach 0.0 0.0 -10.0 -27.8 -15.6 -10.0 -28.0 -22.2 
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Table 3.8 Validation of lorazepam [174] and ceforanide [175] paediatric model against clinical data  
Lorazepam 
 Cmax (ng/ml) AUC (ng.h/ml) Vd (L/kg) 
Simulated 77.14 ± 15.82 1005.62 ± 268.48 1.64 ± 0.13 
Clinical 56.1 ± 44.9 822.5 ± 706.1 1.92 ± 0.84 
Ceforanide 
 Cmax (µg/ml) AUC (µg.h/ml) Vd (L/kg) 
Simulated 60.4 ± 14.4 250 ± 74.0 0.24 ± 0.16 
Clinical 56.3 ± 14.0 215 ± 61.0 0.26 ± 0.67 
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3.4. Discussion 
The validation of the mathematical structure and input parameters of anatomy and 
physiology of children is a pivotal step to support a reliable PBPK modelling ap-
proach. The validation described in this chapter focuses on the anatomical and phys-
iological factors for paediatric and adolescent patients. The anatomy and physiology 
of the paediatric model was validated at different age groups against available data. 
Appropriate allometric equations were selected from available literature sources and 
the mean value of each parameter obtained from the simulation of 100 virtual indi-
viduals was compared against clinical data [129, 178, 179, 181, 183, 185, 186]. For 
major organs/ tissues and blood flow rates, the predicted values were comparable (< 
100 % from the mean value) to available data and a difference of >100 % from the 
mean value was observed for skin weight of 10 year olds in both males and females. 
To further evaluate the reliability of this modelling approach, the pharmacokinet-
ics of an IV administered lorazepam and IM administered ceforanide was also vali-
dated against available clinical data [174]. Lorazepam and ceforanide were selected 
as the validation drugs due to data availability in paediatric patients of the desired age 
group (3-17 years) [174]. The reported IV lorazepam study was conducted in 63 pae-
diatric patients indicating reliability in the presented data and hence was considered 
to evaluate the drug pharmacokinetics in a PBPK model describing children and ad-
olescents. Ceforanide IM simulations provide confidence in simulating the IM com-
partment of the PBPK model. The model was considered validated if the mean phar-
macokinetic parameters (Cmax, Ctrough and AUC) were ± 50 % compared to the clinical 
data and to verify that the PBPK model has the potential of simulating pharmacoki-
netics appropriately. Comparison between simulated and clinical lorazepam and cefo-
ranide pharmacokinetics indicate that the PBPK model validation was successful, 
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suggesting that ADME processes can be implemented in the current mathematical 
framework. Several routes of administration could be potentially implemented in the 
PBPK modelling approach, but for the current chapter, the intravenous and intramus-
cular routes were selected as the primary focus of the thesis is IM LAI Studies have 
shown variable drug clearance and water content that can alter the volume of distri-
bution, protein binding and blood-to-plasma ratio in ageing children [179, 190, 191]. 
. Age dependent differences in fraction unbound and blood-to-plasma ratio could not 
be considered due to unavailability of data and was assumed to be the same across all 
age groups.  
A similar approach was included in previous PBPK applications for paediatric 
patients where the reliability of the predictions was compared against available clini-
cal data [179, 180, 192, 193]. The validated methods have been used to provide quan-
titative prediction of potential dose optimisation strategies for paediatric patients 
across different disease areas. Maharaj et al. simulated the pharmacokinetics of 0.05 
mg/kg intravenous lorazepam in various age groups of paediatric patients ranging 
from 0-18 years [194] and Edginton et al. developed a PBPK model for five com-
pounds - acetaminophen, alfentanil, morphine, theophylline and levofloxacin in pae-
diatric patients ranging from birth to 18 years by scaling down adult clearance values 
at variable doses across age groups [192]. Bjorkman utilised in silico models to sim-
ulate the distribution of theophylline (4 mg/kg, intravenous infusion over 5 min) and 
midazolam (0.2 mg/kg, intravenous infusion over 5 min) in paediatric patients aged 
from 0-18 years as model drugs [179].  
 PBPK modelling is a mathematical representation of pharmacokinetics and there-
fore is based on conceptual and pharmacological assumptions to support a computa-
tional simulation of ADME. The current PBPK model was assumed to have well 
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stirred compartments with instant uniform drug distribution across each tissue and 
organ. The blood circulation was simulated representing local blood flow to major 
tissues and organs as described in section 3.2.3. Although lymphatic circulation might 
mediate drug diffusion for some highly lipophilic compounds, this was not included 
in the current model due to the lack of available data [124]. Also transporters are also 
not considered in the model, which can influence the drug absorption, distribution and 
clearance. Due to unavailability of the data related to the rapid changes in anatomy 
and physiology of neonates and infants, the PBPK model could not be designed for 
these age groups.   
Clinical scenarios characterised by ethical and logistical barriers represent ideal 
areas for applications of the PBPK approach, allowing a more rational design of future 
research. Validated paediatric PBPK models could be used for studying the influence 
of drugs over a wide range of therapeutic areas in patients with comorbidities, organ 
dysfunction, under- and overweight etc. In some cases, paediatric patients are receiv-
ing multiple treatments in several clinical scenarios, therefore the current model could 
find potential in the evaluation of drug-drug interactions. Also, rapid anatomical and 
physiological changes are observed in neonates and infants which could complicate 
the dosing regimens [195]. Earlier reported increased mortality using chlorampheni-
col and sulphonamides indicate the importance of appropriate dose administration 
[167]. PBPK models could close the gap and assist in dose optimisation strategies in 
paediatric patients.  
Additionally, PBPK models could be applied to simulate and predict drug distri-
bution in other special population with specific anatomical and physiological charac-
teristics such as elderly, pregnant women and patients with cirrhosis or other comor-
bidities. The application of computational pharmacokinetic models can support a 
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more detailed understanding of factors influencing drug distribution in different sub-
population of patients facilitating a tailored dose optimisation approach. [111, 196]. 
Regulatory authorities such as FDA and European Medicines Agency (EMA) 
have introduced new regulations where pharmacokinetic modelling is identified as a 
valuable tool to reduce the number of clinical subjects in paediatric clinical studies 
[197, 198]. Thus, PBPK modelling could be an effective tool which could help reduce 
the cost and time in dose optimisation and also assist in detailed understanding of 
drug pharmacokinetics, bridging the gap between in vitro and in vivo data. 
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4.1. Introduction 
Adherence to HIV therapy is one of the major issues hindering treatment effec-
tiveness. Currently available formulations necessitate lifelong, daily dosing and poor 
adherence has been attributed to numerous factors including pill fatigue, side effects 
and a range of social conditions associated with affected populations [121]. Problems 
can be particularly exacerbated in specific sub-populations of patients such as paedi-
atric patients, where drug administration is additionally influenced by the caregiver, 
the family or the social surroundings, which may further complicate this problem 
[199].   
LAI formulations have the potential of improving the adherence issue related to 
oral formulation, reducing the amount of API used for therapy and consequently the 
cost of therapy. The use of LAI formulation in paediatric patients has been already 
hypothesised in different disease areas and sustained therapeutic concentration of 
APIs have been obtained for LAI antipsychotics in children [200]. 
Two LAI ARV formulations have been recently developed and several other are 
currently under investigation [36]. Rilpivirine, due to its long half-life and potency, 
has been selected for monthly LA strategies [87]. Recently a novel HIV integrase 
inhibitor, cabotegravir, was developed by ViiV Healthcare. It has an extended half-
life that potentially allows it to be administered as a LAI once every three months 
through an IM injection [36]. A combination of cabotegravir and rilpivirine LAI for-
mulation is currently in a clinical trial to assess its safety and efficacy in adults [201].  
The identification of safe and effective dosing strategies for paediatric patients is 
complicated by numerous factors. Differences in anatomical and physiological char-
acteristics of children and adolescents compared to adults have a relevant effect on 
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ADME processes and are not correctly captured through allometric scaling approach 
[164]. Additionally, logistic and ethical challenges in designing dose finding/optimi-
sation studies in children limits the number of clinical studies [179].  
PBPK modelling represents a feasible option to optimise doses prior to clinical 
trials in paediatric patients thus minimising the time and cost invested in optimising 
doses. It is a bottom up approach which integrate in vitro data such as apparent per-
meability using Caco-2 cells, intrinsic clearance, protein binding in a mathematical 
description of ADME to extrapolate to in vivo pharmacokinetics [50]. The aim of this 
study was to simulate pharmacokinetics and inform optimal doses of LA IM formu-
lations of cabotegravir and rilpivirine in children and adolescents through PBPK mod-
elling.  
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4.2. Methods 
Children between the ages 3-18 years were categorised into weight groups sug-
gested by WHO, and 100 virtual individuals were generated in each weight category. 
For the development of the PBPK approach, instant and uniform distribution of drugs 
in tissues, no reabsorption of the drug from the large intestine and a blood-flow lim-
ited model were assumed. The PBPK model was constructed using Simbiology® 
v.4.3.1, a product of Matlab® v.8.2 (MathWorks, Natick, MA, USA 2013). Cabo-
tegravir and rilpivirine LA IM pharmacokinetics were assessed and validated in adult 
PBPK models and later optimised for different weight categories of children and ad-
olescents. 
4.2.1. Anatomy 
Adult PBPK model was defined by key characteristics such as age, and weight of 
the individual. These defining characteristic values were further used for the compu-
tation of organs, tissue volumes and blood flow rates through allometric equations as 
described by Bosgra et al. [129]. The anatomy and physiology of children and ado-
lescents was obtained from various literature sources and has been validated against 
available clinical data prior to dose optimisation (Chapter 3). To improve the confi-
dence of the constructed paediatric PBPK model, it was also validated against intra-
venous lorazepam and intramuscular ceforanide as reference drugs (Chapter 3).  
4.2.2. Simulation of ADME processes 
Drug diffusion from the IM compartment obey first-order rate kinetics and the 
equation was obtained from Tegenge et al.[124]. Release rate of cabotegravir was 
obtained from literature [202] and for rilpivirine, it was derived using 48-week clini-
cal data from LATTE-2 study [36]. 
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The intrinsic clearance values derived from in vitro data have been obtained from 
the literature [203] and extrapolated to systemic clearance [204]. The analysis of drug 
distribution to different organs and tissues was performed using previously published 
equations [120]. 
4.2.3. Model validation  
The physicochemical properties of cabotegravir and rilpivirine used in the model 
are represented in Table 4.1. The validation of the drug properties against clinical data 
was conducted in 100 virtual adults for 800 mg quarterly dose of cabotegravir (from 
weeks 12-28) and for a subsequent monthly dose of 900 mg rilpivirine (after the initial 
dose of 1200 mg) [36]. The release rate of rilpivirine was identified from the clinical 
data using the PBPK model [36]. The release rate was also validated against the 
LATTE-2 pharmacokinetic curve of cabotegravir and rilpivirine. Cabotegravir release 
rate was observed to be same, however there was a decrease in the release rate of 
rilpivirine from 0.0009 to 0.0005 h-1, since it was a reformulation of the previously 
published rilpivirine nanoformulation [87, 205]. 
4.2.4. Dose prediction 
After the validation of the physicochemical parameters, the physiology and the 
anatomy has been modified to describe the children and adolescents using appropriate 
allometric equations obtained from the literature [129, 176, 179, 181-183, 206]. Fol-
lowing IM injection, dose optimisation in paediatric patients was conducted such that 
at least 95 out of the 100 virtual individuals had a mean Ctrough over the cut-off limits 
for the required duration. Similar to LATTE-2 study, 10 mg PO Ctrough (1.35 µg/ml) 
value was used as the minimum cut-off value for cabotegravir dose predictions and 
25 mg PO (70 ng/ml) Ctrough was used as the average concentration (Cav) for rilpivirine 
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[205]. An oral dosing regimen for 4 weeks (steady-state) followed by a loading dose 
and eleven maintenance doses for a 4-weekly IM administration of rilpivirine and 
cabotegravir were simulated, for a total period of 52 weeks. 
4.2.5. Sensitivity analysis 
Differential sensitivity analysis was performed as previously described in chapter 
2, section 2.2.10 [135]. Analysis was performed for the loading dose and the first 
maintenance dose of cabotegravir and rilpivirine LA IM formulation in adults. Drug 
plasma concentration was analysed against six parameters – blood-to-plasma ratio, 
cardiac output, clearance, liver weight, protein binding, and release rate by varying 
20 % from its mean value. For each parameter, the simulations were performed for100 
runs while keeping the rest of the parameters constant.  
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Table 4.1 Physicochemical properties, in vitro and population pharmacokinetic 
data of ARVs  
  Cabotegravir Rilpivirine 
Molecular weight 427 366 
log Po:w 1.04 [207] 4.32 [208] 
Protein binding 99.30 % [123] 99.70 % [208] 
pKa 10.04 [207] 3.26 [208] 
R 0.441 [209] 0.67 [208] 
CYP3A4 CLint - 2.04[208] 
UGT1A1 CLint  4.5 [203] - 
UGT1A9 CLint 2.2 [203] - 
Release rate (h-1) 0.00045 [202] 0.0009 [36] 
log Po:w – Partition coefficient between octanol and water; pKa – logarithmic value of 
the dissociation constant; R – blood-to-plasma drug ratio; CLint – intrinsic clearance; 
CYP – cytochrome P450 (µl/min/pmol); UGT - uridine diphosphate glucuronosyl-
transferase (µl/min/mg). 
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Table 4.2 Validation of antiretrovirals at steady state: Clinical [36] vs. simulated pharmacokinetic data and the percent difference 
between them. 
Drug Dose 
(mg) 
AUC 
 
Cmax 
 
Ctrough 
 
Clinical Predicted ∆ Clinical Predicted ∆ Clinical Predicted ∆ 
Cabotegravir 
800 mg 
quarterly 
4467 (52)  5166 (23) -13.5% 3.3 (59) 3.5 (21) -5.7% 1.1 (140) 1.2 (24) -8.3% 
Rilpivirine 
900 mg 
monthly 
74,420 
(35) 
84,270 (44) -11.7% 168 (37) 157 (42) 7.0% 79.1 (44) 72.1 (45) 9.7% 
Values are represented as Geometric mean (% CV – coefficient of variation expressed as a percentage), AUC – area under the concen-
tration-time curve, Cmax – maximum plasma concentration, Ctrough – trough plasma concentration, cabotegravir pharmacokinetics are 
represented as µg/ml for Cmax and Ctrough and µg × h/ml for AUC at day 84, rilpivirine pharmacokinetics are represented as ng/ml for Cmax 
and Ctrough and ng × h/ml for AUC at day 28. ∆ - percentage difference between mean clinical and predicted value 
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4.3. Results 
The PBPK model was initially validated against clinical data for both cabotegravir 
and rilpivirine to ensure that the selected drug properties were appropriate. The phar-
macokinetic parameters mean simulated Cmax, Ctrough and AUC were compared 
against available clinical data for LAI formulations for both these drugs (cabotegravir 
– second IM dose of 800 mg and rilpivirine – 900 mg after the initial dose of 1200 
mg) (shown in Table 4.2 and Figure 4.1). To increase the accuracy  of the simulations, 
the PBPK model was considered validated if the mean value was within 0.5-fold from 
the clinical value instead of the conventional 2-fold limit [152].  
The formulation characteristics were maintained equal for the simulations in pae-
diatric and adolescent patients assuming a similar release rate of the drugs from the 
formulations, hypothesising the use of the same formulations in paediatric and ado-
lescent patients.  IM doses were optimised to have a pharmacokinetic profile over the 
10 mg PO Ctrough for cabotegravir over the duration of treatment and an average con-
centration over the Ctrough of 25 mg PO rilpivirine for the first 12 IM doses (Figure 
4.2). For rilpivirine, it was also ensured that the concentrations are always above 
PAIC90 value subsequent to the loading dose. Summary of predicted doses for both 
cabotegravir and rilpivirine for different weight categories are shown in Table 4.3. 
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c)
 
Figure 4.1 Validation of the PBPK model against clinical data for the second IM 
administration. a) Cabotegravir (800 mg followed by 800 mg quarterly) b) Rilpivirine 
(1200 mg followed by 900 mg monthly) [36] c) Percentage variation of the mean 
simulated pharmacokinetics from the mean clinical data 
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4.3.1. Cabotegravir 
The validation for 800 mg of IM cabotegravir resulted in a  mean predicted AUC, 
Cmax and Ctrough that were at +15.6 %, +6.1 % and +9.1 % compared to  clinical value 
respectively [36]. A target concentration of 1.35 µg/ml (10 mg PO Ctrough) was chosen 
from the literature [36]. The doses for the different weight groups were informed such 
that at least 95 out of the 100 virtual individuals has a Ctrough value over the target 
concentration for a duration of 48 weeks. The monthly oral dose administered for a 
period of 4 weeks was 10 mg for weights ranging between 14-50 kg and 20 mg for 
weights between 50-70 kg. For IM cabotegravir, the loading dose ranged between 
200-600 mg and maintenance doses between 100-250 mg (Figure 4.3) for the simu-
lated plasma Ctrough to stay over the 10 mg PO Ctrough as described in Table 4.3.  
4.3.2. Rilpivirine 
The simulated mean AUC, Cmax and Ctrough values were +13.2 %, -6.5 % and -8.8 
%, compared to the clinical data [36]. After the validation of rilpivirine PBPK model, 
the first order kinetic release rate was identified to be 0.0009 h-1. The validation was 
then performed to find the optimal release rate for rilpivirine pharmacokinetics from 
LATTE-2 study. Due to reformulation of rilpivirine nanoformulation, the optimal re-
lease rate was observed to be 0.0005 h-1 (Figure 4.2). The optimal doses were informed 
for different weight categories such that the average drug Ctrough plasma concentra-
tions of 48 weeks stay over 70 ng/ml (25 mg PO Ctrough) [205]. Fixed oral dose of 25 
mg was administered for 4 weeks prior to IM doses. The loading dose ranged from 
250 – 550 mg and the maintenance doses from 200 – 500 mg across weight groups 
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from 15-70 kg individuals (Figure 4.3). The optimal doses ensured plasma concentra-
tions over the PAIC90 value and average IM concentrations over 25 mg PO Ctrough for 
at least 95 out of 100 individuals.  
a) 
 
b) 
 
Figure 4.2 Validation of the PBPK model against clinical data from 48-week 
LATTE-2 study. a) Cabotegravir b) Rilpivirine [205] 
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Figure 4.3 Dose prediction of loading and maintenance doses of cabotegravir and 
rilpivirine for various weight categories of children and adolescents 
4.3.3. Sensitivity Analysis 
Figure 4.4 shows the mean differential sensitivity analysis plot of 100 runs for six 
chosen parameters with respect to time. The analysis was performed for two succes-
sive (loading and maintenance) monthly IM doses of cabotegravir and rilpivirine in 
adults.  
For cabotegravir, the analysis indicated that the plasma concentration is sensitive 
to only two of the six factors and higher influence was observed in the first days fol-
lowing administration. Cardiac output and systemic clearance of drug had higher sen-
sitivity towards the variation in plasma concentrations. Protein binding, release rate, 
liver weight and blood-to-plasma ratio were negligibly sensitive. This indicates that 
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physiological factors and the UGT content in the liver had higher potential to influ-
ence the simulated pharmacokinetics.  Sensitivity against cardiac output was negative 
for most of the duration indicating an increased effect against plasma concentration 
even when the value changes by ± 20% from the mean. Sensitivity against systemic 
clearance had a similar trend to cardiac output but with lower intensity. During the 
initial days after the administration of maintenance dose, both these factors showed 
positive relationship against plasma concentration indicating lower effect.  
Extent of sensitivity observed for rilpivirine formulation was lower compared to 
cabotegravir. Change in plasma concentration was not sensitive when cardiac output, 
liver weight and release rate varied ± 20 % from the mean. Blood-to-plasma ratio had 
a higher positive effect immediately after dosing implying lower influence on plasma 
concentration. Blood-to-plasma ratio and systemic clearance showed positive rela-
tionship over the entire dosing period indicating decreased effect against plasma con-
centration. Protein binding fluctuated between positive and negative, however the 
variation is minimal signifying minimal or no effect on plasma concentration. 
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Figure 4.4 Differential sensitivity analysis of the key parameters in the PBPK model. 
a) Cabotegravir, b) Rilpivirine 
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Table 4.3 Prediction of the dose (in mg) for loading and maintenance intramuscular injections of cabotegravir and rilpivirine for 
different weight categories. 
Weight (kg) 
Rilpivirine Cabotegravir 
Daily oral 
dose 
Loading 
dose 
Maintenance 
dose 
Daily oral 
dose 
Loading 
dose 
Maintenance 
dose 
14 - 19.9 25 250 150 10 200 100 
20 - 24.9 25 250 200 10 250 100 
25 - 29.9 25 250 200 10 250 100 
30 - 34.9 25 300 250 10 350 150 
35 - 39.9 25 350 300 10 350 150 
40 - 44.9 25 400 300 10 400 150 
45 - 49.9 25 450 350 10 450 150 
50 - 54.9 25 450 400 20 450 200 
55 - 59.9 25 500 400 20 500 200 
60 - 64.9 25 500 450 20 550 200 
65 - 69.9 25 550 500 20 600 250 
Target concentration  
(ng/ml) 
70 (25 mg PO Ctrough) [205] 1370 (10 mg PO Ctrough ) [205] 
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4.4. Discussion 
Optimal treatment adherence is essential to sustain an effective inhibition of the 
viral replication and prevent development of resistance to ARVs. Although oral for-
mulations support therapeutic concentrations, sub-optimal-adherence in patients who 
are receiving drugs daily for treatment and prevention has been described [82, 210-
213]. Alternative administration could further support higher adherence by reducing 
the frequency of administration and improving pill fatigue. More specifically, formu-
lations allowing a monthly or quarterly administration could support higher adherence 
levels, thus decreasing the risk of drug resistance. ARVs with high potency and fa-
vourable pharmacokinetics are essential for the development of these strategies. The 
recent development of LA formulations such as cabotegravir and rilpivirine constitute 
a remarkable step towards addressing this pivotal issue, providing innovative phar-
macological tools [36]. Dose optimisation in special populations of patients such as 
children and adolescents is a challenge due to their unique physiological and anatom-
ical characteristics compared to adults. . The present study aimed to identify dosing 
strategies of cabotegravir and rilpivirine using PBPK modelling.  
Various PBPK models have been developed for adults and recently this modelling 
technique has also been used for paediatric and adolescent patients [194, 214]. Drug 
distribution can be simulated in this special population of patients through the inte-
gration of age-related anatomical and physiological changes into the mathematical 
PBPK framework. PBPK modelling has been recently used for the prediction of mid-
azolam and theophylline in neonates, infants and children [179]. In two other studies, 
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relationship between adult and paediatric clearance rate was established using cyto-
chrome P450 ontogeny for six compounds and then simulations were performed for 
five different drugs at different age groups [192, 215]. An oseltamivir PBPK model 
was used to predict pharmacokinetics in neonates and infants with influenza [193] 
and a disease specific model was also recently developed in children with and without 
liver cirrhosis [216]. 
Both cabotegravir and rilpivirine are characterised by long-half lives and physi-
cochemical properties that are compatible with nanoformulations for LAI, represent-
ing attractive options for continuous therapy [36, 123]. Using physiochemical prop-
erties and in vitro data, the pharmacokinetics of cabotegravir and rilpivirine in adults 
was validated against clinical data conducted in adults. The model validation was 
conducted at the second dose of the LA ARVs to have a mathematical representation 
of the pharmacokinetics at steady-state. Low accuracy and precision was observed in 
ÉCLAIR study where the simulated Ctrough value of cabotegravir was 1.35 µg/ml com-
pared to the observed value which was less than 0.66 µg/ml (4*PAIC90) [217]. Hence, 
stringent guidelines were applied for the validation process where ± 50 % deviation 
from the mean clinical values was considered acceptable instead of the conventional 
2-fold deviation [152]. The pharmacokinetic parameters – AUC, Cmax and Ctrough sim-
ulated through the PBPK approach were in agreement with the clinical data and there-
fore our PBPK model was considered robust for predicting the LA IM doses in pae-
diatric and adolescent patients. In the simulation of LA pharmacokinetics in children, 
the release rates of the LA formulations were maintained equal to the validation in 
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adults, to ease the bridging of the formulations for paediatric use. Although the phys-
iology of the muscular tissues is different between adults and children, this could po-
tentially support the use of the existing formulations in paediatric clinical studies with 
no further reformulation [218]. However additional studies are required since there is 
a possibility that smaller doses with less injection volume could decrease total surface 
area and strain in the muscle, thereby altering the pharmacokinetic profile. The doses 
were optimised such that the cabotegravir and rilpivirine concentrations were over the 
assumed cut-off limits (described in methods section) for the duration of the dose. 
Although PAIC90/95 values indicate a cut-off limit to suppress the virus in vitro, this 
does not translate in effective therapeutic activity in vivo [154]. Therefore, the dose 
optimisation was also conducted considering LATTE-2 study cut-off values. 
Two different cut-offs – PAIC90/95 and MEC were chosen such that different doses 
could be prescribed either for PrEP or therapy. The required dose was proportional to 
the weight of the individual, which indicates an increase in volume of distribution. 
Required dose of cabotegravir tripled as the weight increased from 15 to 70 kg com-
pared to rilpivirine which required just over double the dose. This indicates that doses 
cannot be linearly extrapolated based on weight and a deeper understanding of im-
portant mechanistic processes influencing the pharmacokinetics in children and ado-
lescents is required. The loading doses are higher compared to the maintenance doses 
as the extra dose is essential to maintain drug plasma concentrations over the 
Ctrough/PAIC90 values. 
LAI formulations improve the problems faced with low adherence of ART in chil-
dren. Focus on the clinical evaluation of the paediatric dose in patients should also be 
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given priority as most of the prescribed drugs are scaled from adult doses. Chloram-
phenicol dose scaling from adults in neonates and infants reached toxic levels which 
led to higher mortality rate, an example where the developmental pharmacology of 
paediatric patients was ignored [219]. Mortality rate was higher in neonates affected 
with kernicterus who were administered penicillin/sulfisoxazole than with oxytetra-
cycline in an another case [220]. In both these cases, an immature glucuronidation 
system led to the accumulation of drug, resulting in high plasma concentrations and 
conclusively demonstrating that the physiological processes of the child cannot al-
ways be accounted for by scaling adult doses [167, 220]. 
Although the informed doses for children could represent an initial guideline for 
drug safety and efficacy studies, a few processes have not been mathematically de-
scribed in the model regarding the anatomy and physiology of paediatric patients and 
associated complex biological processes due to unavailability of data [124]. Low clin-
ical Cmax (Figure 4.1) compared to the simulated pharmacokinetic curve could be due 
to the fraction of drug distributed through the lymphatics. Absence of information on 
drug transporters at the depot site for these drugs could alter the absorption, distribu-
tion and metabolic processes which could not be captured in the PBPK model. Recent 
investigation with paliperidone LAI micro suspension revealed formation of a granu-
loma due to macrophage accumulation surrounding the site of injection. This phe-
nomenon further controlled drug release from the depot and evidence also showed 
drug uptake and release from macrophages [79]. The extent of the occurrence of this 
phenomenon and the size of the depot could alter the release rates and thereby drug 
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pharmacokinetics which was not accounted for in this study. Physiological and met-
abolic variation of muscle composition in children compared to adults was not ac-
counted during the dose optimisation process [218]. The potential adverse effects con-
sidering the differences in the anatomy and physiology of children compared to 
adults, prolonged exposure and inability to discontinue therapy once administered are 
important factors to be assessed before drug administration [121]. 
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6. In vitro experimental design to 
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5.1. Introduction 
Nanotechnology has advanced a lot in the past decade paving a way for designing 
novel formulations with prolonged drug release. Recent advances in polymer science 
greatly aided in design of controlled release formulations with particle sizes ranging 
between nano- and micrometres[221]. Polymer content assists fine-tuning drug re-
lease from the formulation to suit physiological conditions and simultaneously meet 
pharmacological requirements [221]. Several articles have been published based on 
micro- and nanoformulations consisting of water-soluble, biodegradable polymers 
such as chitosan, poly (lactic-co-glycolic acid) etc. that not only encapsulate the drug 
and control its release from the particles but are also biodegradable and biocompatible 
[222, 223].  
Formulation design to support LA release can be complicated by the lack of ex-
perimental approaches to characterise drug release from the site of injection. Drug 
release can be quantified in preclinical species but this approach has numerous short-
comings such as physiological and anatomical differences between the selected spe-
cies and humans, as well as high costs [87, 224, 225]. In vitro methods could represent 
a cost-effective and faster strategy to assess drug release and therefore support a ra-
tional selection of lead candidates [226].  
To date, the United States Pharmacopeia (USP) does not identify a standard pro-
cedure to evaluate LA IM or SC formulations in vitro. Although in vitro release meth-
ods such as basket (USP apparatus 1), paddle (USP apparatus 2), paddle over disk 
(USP apparatus 5), cylinder (USP apparatus 6) and reciprocating disk (USP apparatus 
7) exist, they are specifically recommended for oral and transdermal formulations 
based on the use of large volumes of media.  USP apparatus 3 is not suitable for small 
particulate formulations less than 420 µm, characterised by media evaporation for 
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longer duration experiments which could lead to wide variability in sampling and 
might not maintain sink conditions for sparingly solubilized drugs [227]. Drawbacks 
of USP apparatus 4 includes a stationary compartment for the formulation, leading to 
aggregation of the micro- or nanoformulations and usually has a high flow rate (≥ 2 
ml/min) [228]. Therefore, there is a pivotal need to design a standard in vitro system 
to effectively assess the release profile of LA formulations.  
Experimental in vitro methods have been preliminarily developed for the investi-
gation of oil-based formulations. A rotating dialysis cell method was used to access 
release of flupentixol, bupivacaine and naproxen LA formulations based on fraction-
ated coconut oil [229, 230], lidocaine and testosterone in castor oil [231]. A bulk 
equilibrium reverse dialysis bag technique was applied for the quantification of drug 
release for oil-in-water emulsions using phenylazoaniline and benzocaine as model 
drugs, mimicking the in vivo environment [232]. However, all these reported in vitro 
methods do not compare drug release against any in vivo or clinical data. Although 
these studies were focusing on oil-based formulations, water-based formulations have 
wider clinical applications due to their good tolerability at the injection site compared 
to oily formulations [233].  
Lately, few in vitro methods have been used to evaluate the drug release from 
water-based LAI formulations. Microspheres made of poly-D, L-lactide containing 
indomethacin were compared across four in vitro dissolution apparatuses – USP 2 
dissolution apparatus, rotating bottle, shaker incubator and modified flow-through 
cell [234]. Large molecules such as lysozymes encapsulated in PLGA microspheres, 
gelatin microspheres containing oligonucleotides and DNA-fragments were analysed 
using flow-through cell method that could differentiate the drug release pattern be-
tween various formulations [235, 236].  
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The aim of this chapter was to evaluate three different types of in vitro release rate 
experiments, namely microdialysis using rapid equilibrium dialysis membranes, 
flow-through cell dialysis and sample-and-separate methods. These in vitro methods 
were evaluated using commercially available LAI formulations of Depo-provera 
(medroxyprogesterone acetate), Risperdal consta (Risperidone), Xeplion (Paliperi-
done palmitate), Zypadhera (Olanzapine pamoate) and a test formulation of rilpi-
virine. The obtained in vitro release rates were then correlated against PBPK release 
rates to identify the predictive capability of these in vitro methods.  
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5.2. Materials and Methods 
5.2.1. Materials used 
Bovine serum albumin (Sigma, UK), γ-globulin (Sigma, UK), Depo-provera® 150 
mg/ml medroxyprogesterone acetate (Pfizer Limited, UK), Xeplion® 100 mg/ml pal-
iperidone (Janssen, UK), Zypadhera® 150 mg/ml olanzapine (Elli Lilly, UK), 
Risperdal Consta® 25 mg/ml risperidone (Janssen, UK), 300 mg/ml rilpivirine 
(Janssen, UK), phosphate buffer saline (Life Technologies, UK), isopropyl alcohol 
(Fisher Scientific, UK), docusate sodium (Sigma, UK), methanol (Sigma, UK), acetic 
acid (Fisher Scientific, UK), acetone (Sigma, UK), Float A Lyzer® G2 dialysis tubes 
100 KDa MWCO (Spectrum Laboratories, UK), 0.3 ml and  1.8 ml high performance 
liquid chromatography (HPLC) vials (Thermo Scientific, UK), rapid equilibrium di-
alysis (RED) tubes 8 KDa MWCO (Thermo Scientific, UK), Fetal Bovine Serum 
(FBS) (Life Technologies, UK), Phosphate Buffered Saline (PBS) tablets (Sigma, 
UK). 
5.2.2. Equipment used 
Classic series New Brunswick Scientific Incubator (NJ, USA), Stuart scientific 
rotator drive STR4 (Chelmsford, UK), Scientific Industries Vortex Genie 2 (NY, 
USA), Thermo Electron Corporation IEC MicroCL 17R centrifuge (MA, USA), Di-
onex HPLC machine (Dionex, Germering, Germany), Fortis 3 µm C18 chromato-
graphic column (Cheshire, UK), Jouan RC 10.10 rota evaporator (Nantes, France), 
Minitab Statistics package (Coventry, UK). 
5.2.3. Static release experiments 
Simulated interstitial fluid (SIF) was prepared by dissolving 3.5 g bovine serum 
albumin and 0.2 g γ-globulin in 100 ml distilled water [237]. The drug formulation 
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prior to use was dispersed by shaking the provided container according to the instruc-
tions provided by the product label. The average pore size of the dialysis tubes is less 
than ~2 nm (8000 Da) which prevents the transfer of intact nanoparticles. In the RED 
dialysis tubes, the maximum volume that could be accommodated is 500 µl and 1 ml 
in the donor and acceptor compartments respectively. Hence, 200 µl of the drug for-
mulation along with 300 µl of SIF was added to the donor compartment and 1 ml SIF 
was added to the acceptor compartment (Figure 5.1). 0.6 ml SIF in acceptor compart-
ment was replaced with fresh SIF at 0.5, 1, 2, 3, 4, 5 and 6 h from the onset of the 
experiment. During sample collection times, the contents of the donor compartment 
were agitated using a pipette to prevent sedimentation of the suspension. The whole 
setup was covered using parafilm to prevent eater evaporation. The collected samples 
were extracted (described in section 5.2.6) and analysed in HPLC (described in sec-
tion 5.2.7). 
 
 
Figure 5.1 Rapid equilibrium dialysis system with drug particles in the donor com-
partment and the solubilised/diffused drug in the acceptor compartment 
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5.2.4. Sample-and-separate method 
A sample-and-separate method obtained from Shen et al. has been used for release 
rate assessment [238]. A 200 µl aliquot of formulation was dispersed into 250 ml of 
PBS. The experiment was conducted aseptically to avoid bacterial growth in the me-
dium. This apparatus was rotated at 100 rpm in a water bath at 37 °C. 1 ml samples 
were taken at regular time points daily for 30 days. The collected samples were cen-
trifuged at 2100 x g for 3 minutes and 0.9 ml of supernatant fraction was collected. 
The remaining was reconstituted using 0.9 ml fresh PBS and was added back to the 
apparatus to maintain a constant volume. The collected samples were filtered through 
0.22 µm filters prior to HPLC analysis. Medroxyprogesterone and rilpivirine were not 
filtered since the drug was retained in the filter. The sample collection and replace-
ment of PBS were done under sterile conditions to avoid bacterial growth in the con-
tainer. 200 µl of the collected samples were transferred to HPLC vials and analysed 
by a HPLC (described in section 5.2.7). 
5.2.5. Dynamic release experiments 
Dialysis tubes were soaked according to manufacturer’s instructions in 10 % iso-
propyl alcohol (IPA) for 10 minutes to remove the glycerine coating from the dry 
dialysis membrane. The dialysis device was rinsed and soaked in distilled water for a 
further 20 minutes to wash off the IPA and the glycerine residue. 
Key parameters such as composition of the media, volume in the donor compart-
ment and flow rate were optimised using Taguchi’s design of experiments to obtain 
maximum drug release from the dialysis tubes. The optimised parameters are men-
tioned here - the donor compartment was made up to the correct dilution using phos-
phate buffer saline (PBS) as 200 µl drug and 3.8 ml PBS. Drug/PBS solution was 
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deposited into the float-a-lyzer dialysis tube, and this apparatus was placed in a falcon 
tube with an inlet and outlet. The lid of the falcon tube was sealed with a glue gun 
and the falcon tube was securely strapped to the rotator plate and placed in an incu-
bator at 37 °C.  
 
Figure 5.2 The apparatus used for dynamic release experiments. The media was 
pumped using the HPLC at a constant flow rate into the acceptor compartment of the 
falcon tube and the sample was collected from the outlet of the tube into a beaker. 
The rotator was programmed such that it would rotate from -90° to +90° to and 
fro to avoid tangling of the pipes connecting the falcon tubes. Vibration of 1° for 1 
sec was also set in the rotator for every rotation to induce additional agitation. 800 ml 
of 50 % FBS/50 % PBS solution was prepared and was pumped into the acceptor 
compartment with the help of a HPLC pump at a flow rate of 0.5 ml/min (Figure 5.2). 
This whole apparatus was placed in an incubator chamber maintained at an ambient 
temperature of 37 °C. The experiment was conducted for 24 h and the sample was 
collected into another beaker from the outlet of the falcon tube. The collected media 
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at 24 h was extracted (described in section 5.2.6) and analysed by HPLC (described 
in section 5.2.7). 
5.2.6. Sample extraction 
A 200 µl aliquot of the samples was transferred to new eppendorfs and mixed with 
1 ml 100 % acetone (for medroxyprogesterone acetate and rilpivirine) or 99.9 % ace-
tonitrile and 0.1 % acetic acid (for olanzapine, paliperidone and risperidone). These 
samples were placed in a rotator for 60 min to allow the transfer of dissolved drug 
from the aqueous phase to the organic phase. Following this, samples were centri-
fuged at 13,300 rpm for a further 30 min to precipitate the plasma proteins. The su-
pernatant fractions were transferred to glass vials and left to dry overnight at room 
temperature in a rotary evaporator under vacuum. The following day, 200 µl of the 
appropriate reconstitution liquid (described in section 5.2.7) was added to the dry res-
idue, which was then transferred to 300 µl vials for HPLC analysis. 
5.2.7. HPLC analysis protocol 
In order to analyse samples obtained from dialysis experiments, it was necessary 
to produce a standard curve using known concentrations of drug; standards from 39 
to 20,000 ng/ml were used. This calibration curve was then used to calculate the drug 
amount in the unknown samples. A Dionex HPLC with UV detection was used for 
analysis, injection volume was set at 100 µl and a Fortis C18 column (3 µm, 4.6 x 100 
mm) with a Fortis C18 Guard (3 µm, 4 x 10 mm) at room temperature was used for 
chromatographic separation in this process. 
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5.2.7.1. Medroxyprogesterone acetate 
The mobile phase A consisted of 60: 40 water: methanol with 3 mM docusate 
sodium, 10 ml acetic acid and perchloric acid to adjust the pH to 3 in a one litre solu-
tion and 100 % methanol was used as mobile phase B. The gradient started with 50 
% B at 0 min; 50 % B at 0.2 min; 90 % B at 0.5 min; 90 % B at 6.0 min, 50 % B at 
6.1 min and the run time was set to 8 min. Flow rate was set at 0.8 ml/min and 254 
nm was used as the wavelength to detect medroxyprogesterone acetate. The extracted 
samples were reconstituted with mobile phase A. The retention time observed was 
5.24 min. 
5.2.7.2. Olanzapine 
Mobile phase A comprised 95: 5 10 mM potassium phosphate: acetonitrile and 
orthophosphoric acid was used to adjust the pH to 4. Mobile phase B consisted of 90: 
10 acetonitrile: water. The flow rate of the mobile phase was set to 1 ml/min and the 
run time was 8 min. The gradient employed was 10 % B at 0 min, 10 % B at 0.5 min, 
80 % B at 4 min, 80 % B at 6 min, 10 % B at 6.1 min. The UV detection wavelength 
was 257 nm. 80: 20 mobile phase A: acetonitrile was used as the reconstitution solvent 
for the analyte and the retention time was observed to be 4.56 min. 
5.2.7.3. Paliperidone 
Mobile phase A consisted of 95: 5 5 mM ammonium formate: acetonitrile and 
formic acid to adjust the pH to 4 and 90: 10 acetonitrile: water as mobile phase B. The 
flow rate was 1 ml/min and the composition of the mobile phase was varied as fol-
lows: 0 min: 10 % B, 0.5 min: 10 % B, 4 min: 95 % B, 6 min: 95 % B, 6.1 min: 10 % 
B and 8 min: 10 % B. The run time was set to 8 min and the retention time of the 
analyte was observed to be approximately 4.82 min. The reconstitution solvent used 
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to analyse the samples consisted of 80 % mobile phase A and 20 % acetonitrile. The 
detection wavelength used was 257 nm. 
5.2.7.4. Risperidone 
Mobile phase A was 95: 5 5 mM ammonium formate: acetonitrile and formic acid 
to adjust the pH to 4 was used as and 90 % acetonitrile with water was used as mobile 
phase B. The gradient started with 0 min: 20 % B, 0.2 min: 20 % B, 3 min: 100 % B, 
6 min: 100 % B, 6.1 min: 20 % B, 8 min: 20 % B. 260 nm was used as the wavelength 
to detect risperidone. The extracted samples were reconstituted with 80 % mobile 
phase A and 20 % acetonitrile. The retention time observed was 5.67 min. 
5.2.7.5. Rilpivirine 
Mobile phase A comprised 95:5 10 mM potassium phosphate: acetonitrile and 
orthophosphoric acid was used to adjust the pH to 4. Mobile phase B consisted of 
90:10 acetonitrile: water. The flow rate of the mobile phase was set to 1 ml/min and 
the run time was 8 min. The gradient employed was 0 min: 10 % B, 0.5 min: 10 % B, 
4 min: 80 % B, 6 min: 80 % B, 6.1 min: 10 % B, 8 min: 10 % B. The UV detection 
wavelength was 257 nm. 80:20 mobile phase A: acetonitrile was used as the reconsti-
tution solvent for the analyte and the retention time was observed to be 5.09 min. 
Table 5.1 Physicochemical properties and drug specific parameters of drugs 
  
log Po:w 
Solubility in 
H2O (g/L) 
Fraction 
unbound 
Mean parti-
cle size 
(nm) 
Medroxyprogesterone acetate 3.5 [239] 0.0221 [239] 0.1 [239]  2,500 [240] 
Olanzapine 3.39 [241] 0.094 [241] 0.07 [241] 7400 [242] 
Paliperidone 1.76 [243] 0.03 [243] 0.26 [243] 1090 [79] 
Rilpivirine 4.32 [244] 0.0116 [244] 0.003 [139] 200 [87] 
Risperidone 3.27 [245] 0.0028 [245] 0.12 [245] 57,900 [246]  
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5.3. Results 
5.3.1. Static release experiments 
The cumulative drug release obtained during the sample analysis with the HPLC 
in 6 h are presented in Figure 5.3. Rilpivirine did not show any detectable amount of 
drug in the acceptor compartment.  The slope obtained from the best fit line is con-
sidered as the in vitro release rate in h-1. The regression value for all the four formu-
lations is >0.90 indicating a linear, steady drug release into the acceptor compartment. 
Except for medroxyprogesterone acetate, it can be observed that the extent of release 
at 0.5 h is lower than the best fit line implying that the formulation takes some time 
to release the drug in a new environment. An additional sample was collected at 24 h 
(data not shown) but the drug release was limited indicating the saturation of SIF in 
the acceptor compartment after a few hours. 
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b) 
 
c) 
 
d) 
 
Figure 5.3 Summary of the cumulative drug release (n=3) from rapid equilibrium 
dialysis tubes for a) Medroxyprogesterone, b) Olanzapine, c) Paliperidone and d) 
Risperidone. 
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5.3.2. Sample-and-separate method 
The cumulative formulation release trend of the drugs in PBS over a period of 30 
days is shown in Figure 5.4. The variation in the percentage of the drug released over 
time from the formulation is minimal from day 1 to day 30 for all the drugs except 
risperidone. 
 
 
Figure 5.4 Percentage of drug released from the total formulation against time in days 
is shown for the five drugs. a) Medroxyprogesterone, b) Risperidone, c) Olanzapine, 
d) Rilpivirine and e) Paliperidone 
 
Table 5.2 compares the observed vs. expected release from the formulation. Rilpi-
virine and risperidone are the only two among the five assessed drugs to have an ob-
served percent release, over a period of 30 days, close to the expected release by a 
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factor of two (as shown in Table 2). This could be due to limited solubility of drugs 
in PBS. The percentage release is far off from the expected value implying that this 
in vitro method to evaluate drug release is not suitable for long-acting micro- or 
nanoformulations.  
Table 5.2 Summary of the percentage of drug released in vitro using sample and 
separate method and the expected release in 30 days  
Formulation In vitro release for 30 
days (%) 
Expected release for 30 
days (%) 
Medroxyprogesterone acetate  1.28 ~ 45 
Olanzapine  17.3 > 90 
Paliperidone  0.02 > 90 
Rilpivirine  21.5 ~ 35 
Risperidone 46.2 ~ 100 
 
 
5.3.3. Dynamic release experiments 
Medroxyprogesterone acetate was used to optimise the parameters for the dy-
namic release experiments initially. Taguchi’s design of experiments was used with 
two values for each of the three parameters (Table 5.3). Maximum release was ob-
served with 4 ml in the donor compartment (comprising 200 µl drug and 3.8 ml PBS), 
flow rate of 30 ml/h through the falcon tube and 50 % FBS in PBS as the composition 
of media circulated through the tube for 24 h (Table 5.6, Figure 5.5). Drug release 
with 50 % FBS in PBS has more release of medroxyprogesterone compared to 10 % 
FBS. High flow rate (6 vs 30 ml/h) and higher volume in the donor compartment (1 
vs 4 ml) increased the overall drug amount released. To confirm the selection of op-
timum parameters, ANOVA analysis (Table 5.4) and signal-to-noise ratios (Table 
5.5) were performed in Minitab.  
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Table 5.3 Summary of the parameter values and the amount of medroxyproges-
terone released over time using Taguchi’s design of experiments 
Volume in donor 
Compartment (ml)† 
Flow rate (ml/h) % FBS in PBS In vitro release per 
day (µg) 
1 6 10 0.000001 
1 6 50 0.005668 
1 30 10 0.027212 
1 30 50 0.038025 
4 6 10 0.013714 
4 6 50 0.048315 
4 30 10 0.037924 
4 30 50 0.084854 
† Donor compartment consists of 200 µL medroxyprogesterone acetate and 0.8 ml or 
3.8 ml phosphate buffered saline  
 
Figure 5.5 Release of medroxyprogesterone after 24 h using different release condi-
tions; † Donor compartment consists of 200 µL medroxyprogesterone acetate and 0.8 
ml or 3.8 ml phosphate buffered saline 
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Table 5.4 One-way ANOVA analysis for the eight experiments conducted using 
Taguchi’s design of experiments for medroxyprogesterone. The P-value of each 
factor when compared with the release is also shown 
 
Table 5.5 Response table for signal-to-noise ratios for the three parameters as-
sessed for optimisation process. The lower the value, the optimum the level 
No. A - Volume in donor 
Compartment (ml) 
B - Flow rate 
(ml/h) 
C - % FBS in PBS 
1 -46.16 -47.13 -44.25 
2 -28.36 -27.39 -30.27 
Delta 17.8 19.74 13.98 
Rank 2 1 3 
 
Table 5.6 Summary of the parameters considered to have major effect on the 
drug diffusion through the dialysis membrane 
No. A - Volume in donor 
Compartment (ml) 
B - Flow rate (ml/h) C - % FBS in PBS 
1 1 6 10 
2 4 30 50 
 
Following the optimisation process, these parameters were used for the dynamic 
release experiments to conduct release experiments for the rest of the drugs. The 
summary of the results are shown in Table 5.7.  
  
 Release vs. Volume Release vs. Flow rate Release vs. % FBS 
1 ml 4 ml 6 ml/h 30 ml/h 10 % 50 % 
Arithmetic Mean 0.01775 0.0462 0.0169 0.047 0.01974 0.0442 
Standard Deviation 0.01787 0.0296 0.0216 0.0257 0.01642 0.0326 
95 % CI 
(-0.01214, 
0.04764) 
(0.0163, 
0.0761) 
(-0.0121, 
0.0460) 
(0.0179, 
0.0761) 
(-0.01186, 
0.05133) 
(0.0126, 
0.0758) 
P-value 0.151 0.124 0.229 
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Table 5.7 Summary of in vitro release values in 24 h obtained from dynamic re-
lease experiments 
Formulation 
In vitro release 
in 24 h (mg) 
% of initial 
dose released 
% expected 
drug release 
Medroxyprogesterone acetate  0.425 1.4 ~1.5 
Olanzapine  17.06 56.9  ~3.0 
Paliperidone  18.43 92.2 ~3.0 
Rilpivirine  0.05 0.1 ~1.17 
Risperidone 0.431 17.2 ~3.3 
 
The comparison of expected vs. observed percentage of drug amount released over 
24 h is shown in Table 5.7. This indicates a suitable method for medroxyprogesterone 
acetate. However, for olanzapine, paliperidone and rilpivirine the observed release is 
>11 times than the expected release and <5 times for risperidone. 
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5.4. Discussion 
A standardised in vitro test to evaluate drug release from LA formulations has not 
been validated till date. Currently, the majority of the studies to inform the selection 
of formulations are directly performed in vivo primarily in rats, rabbits, dogs and 
monkeys prior to human clinical trials. This strategy has several limitations, is com-
plex, expensive, laborious, often not reproducible, and results in the sacrifice of many 
laboratory animals during development. Consequently, the design of a validated and 
reproducible experimental assay would provide an essential  tool to identify optimal 
candidates prior to in vivo studies [205]. 
Various LAI antipsychotics and contraceptives are already used clinically [248]. 
These commercially available formulations were used as reference drugs to evaluate 
three in vitro methods to characterise the drug release from conditions mimicking the 
physiological depot environment. Evaluation of release rate by reducing the overall 
complexity involved in the design and cost was the primary rationale behind shortlist-
ing these three experimental setups. Microdialysis which utilizes low amount of me-
dia, was the first choice for performing in vitro experiments. RED tubes attain equi-
librium between donor and acceptor compartments quickly and a short experimental 
duration is sufficient to identify the initial release pattern. Figure 5.1 indicate a linear 
correlation between time and amount of drug released into the acceptor compartment. 
After the 6 h time point, an additional sample was collected at 24 h (data not shown) 
and the drug amount accumulated was way below expected indicating saturation of 
drug due to low drug solubility in the limited water content present in acceptor com-
partment. There were a few cases where media in the acceptor compartment dried up 
due to evaporation of water in both compartments when the experiment was con-
ducted for a prolonged period of time. Drugs that bind to the filter membrane or the 
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container made of polymer cannot be analysed using this method. Although these 
experiments do not represent ideal physiological conditions, they could be used as a 
short duration high throughput screening option for rapidly evaluating potential LAI 
formulations. 
The sample and separate method was adapted from Shen et al. and performed 
without the aid of dialysis tubes [238]. This method was used to evaluate drug release 
from formulations into the medium without any barrier. Since this experiment was 
performed at 37 ºC in PBS for 30 days, the sample collection was conducted under 
aseptic conditions to avoid any microbial contamination. Figure 5.4 shows significant 
increase in drug release for risperidone especially in the last 5 days compared to other 
drugs which indicate excipient degradation of the microparticles. There was no sub-
stantial change in percentage of drug released (< 5 %) for rest of the formulations on 
the last day compared to the release on the first day. Solubility in PBS could be the 
limiting factor for the amount of drug released. Aggregation of micro- or nanoparti-
cles could affect the drug release profiles. When using small volumes of media, loss 
of drug during filtration could be a problem. Also drugs that bind to the filter cannot 
be assessed using this method. This method may be suitable for larger particle sizes 
and also drugs soluble in PBS. 
The flow-through cell dialysis technique utilises large amounts of media pumped 
using a HPLC pump through a falcon tube containing the formulation packed in a 
dialysis bag. SIF was replaced with a cheaper alternative – FBS and PBS. Taguchi’s 
design of experiments assisted in the identification of factors influencing drug release 
rates i.e. volume in donor compartment, flow rate through falcon tube and composi-
tion of media in order to achieve maximum drug release. Blood flow through the IM 
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depot was identified as 29 ml/h and therefore flow rate was set at 0.5 ml/min to sim-
ulate this [124]. Four millilitres of fluid was assumed to be present at the site of in-
jection including maximum injection volume (2 ml) and interstitial fluid surrounding 
it. Higher protein content (10 % vs 50 %) in the media improved drug release across 
the dialysis membrane. Table 5.3 indicates that these parameters are the limiting fac-
tors that control drug release from formulation. The flow-through cell method tackles 
media saturation and evaporation observed in microdialysis experiments however it 
is 18 h longer utilising large media volumes compared to the static release experiment. 
Also, clogging of HPLC tubing with proteins from the media could result in large 
variation across samples.  
Various factors affect the drug release from the encapsulated particles. Few of 
them include drug protein binding, solubility in the used media, effect of the excipi-
ents in the media, amount of media, type of agitation, mean particle size, log P and 
the duration of the experiment. From this study it would be difficult to identify the 
individual impact of each of these factors since a simultaneous effect of all the above 
mentioned factors would be observed during the experiments. Due to these factors, it 
would be difficult to compare experimental methods since two or more factors are 
varied across the performed experiments. Secondly, comparison across different drug 
formulations using a single method would be inconclusive since different drug phys-
icochemical properties and formulation characteristics come into play. However, 
from the dynamic dialysis release experiment conducted using medroxyprogesterone 
(Table 5.3), there is a clear-cut influence of drug release due to an increase in the total 
volume present in the donor compartment, flow rate and the percentage of FBS in 
PBS. This indicates that drug release is facilitated with more volume of media in con-
tact with drug formulation and increased protein content. 
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In summary, this chapter indicates that microdialysis and flow-through cell dialy-
sis techniques could have potential for evaluating drug release profiles in vitro with 
lower particle sizes. The sample and separate method is suitable for particle sizes 
greater than 100 µm in diameter. Evaluation using in vitro techniques limits the ability 
to simulate physiological conditions but could provide initial release profiles. Release 
rate is also affected due to various physiochemical factors such as octanol-water par-
tition coefficient, solubility, protein binding, particle size etc. Additional formulations 
with particle sizes ranging between nano-micro ranges should be evaluated in order 
to obtain a robust understanding of the effect of these factors on influencing release 
rate.
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7. In vitro - in vivo extrapolation 
of intramuscular release rate
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6.1. Introduction 
IVIVE is a bottom-up technique that utilises in vitro experimental data to predict 
the behaviour of drugs in vivo. This approach identifies a mathematical correlation 
between data generated using experimental in vitro methods and animal or human in 
vivo data. IVIVE can also be integrated in a comprehensive evaluation of factors in-
fluencing pharmacokinetics, combining drug physicochemical data such as logP, pKa 
etc., drug specific parameters such as intrinsic clearance, Papp etc., and human ana-
tomical and physiological parameters such as organ weights and volumes, cardiac 
output, blood flow rates etc. to simulate the pharmacokinetics in humans through 
compartmental models [249].  
IVIVE can support generation of data without the need of performing complex 
experiments in pre-clinical species or humans. Consequently, results obtained from 
preliminary in vivo experiments could be confirmed rather than being explored using 
IVIVE reducing the time and effort during optimisation. Although IVIVE has been 
applied successfully in drug discovery, it is characterised by limitations. IVIVE con-
siders only the median value to describe a valuable correlation which defines the risk 
of poor prediction for data with extreme values. Variation among different races and 
ethnicities may not be considered which leads to biased results when several popula-
tion types are being analysed. Limited data used for IVIVE could lead to biased results 
and could be applicable only to patients with similar characteristics [232, 250, 251].  
Numerous IVIVE models have been published in recent years to extrapolate 
ADME processes [57, 133, 252, 253]. The correlation of in vitro apparent permeabil-
ity and intrinsic clearance to effective permeability and human intestinal first-pass 
metabolism was characterised using a broad range of compounds [57]. The fraction 
unbound in microsomes was demonstrated to correlate with various drug specific 
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characteristics such as plasma protein binding, blood-to-plasma ratio, acidic phospho-
lipid and neutral lipid content and drug ionisation in plasma and erythrocytes [252]. 
Competitive inhibition and time-dependent CYP3A4 inactivation was predicted using 
enzyme inactivation, synthesis and degradation rate constants and inhibitor concen-
trations in the liver [253]. Tissue-to-plasma drug distribution and volume of distribu-
tion were predicted based on parameters such as logP, pKa, plasma protein binding, 
blood-to-plasma ratios and tissue composition (volume of neutral lipids, phospholip-
ids and water) [133]. 
The mechanistic backbone of PBPK models is the combination of IVIVE equa-
tions and a mathematical description of physiological and anatomical factors of vir-
tual individuals. In vitro data such as passive permeability, the role of transporters, 
and intrinsic clearance, which describe the ADME processes are integrated into PBPK 
models to inform simulation of drug pharmacokinetics in virtual individuals [249]. 
Currently, LAI formulations are evaluated in preclinical species (such as rats, dogs, 
rhesus macaques) prior to studies in humans [121]. Experimental in vitro methods 
that characterise the release rate of LAI formulations prior to preclinical studies could 
present a useful tool to identify valuable lead candidates.  
The aim of this chapter was to conduct an IVIVE by correlating in vitro experi-
mental release rates obtained in Chapter 5 and PBPK predicted release rate for LAI 
formulations with the objective of extrapolating in vitro to in vivo release rate for 
future novel formulations.  
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6.2. Methods 
Previously published PBPK models, validated for IM LAI formulations were used 
to derive the IM release rate from the marketed formulations (Chapter 2). PBPK mod-
els for medroxyprogesterone acetate, paliperidone palmitate, olanzapine pamoate and 
risperidone were developed using available physicochemical and experimental data 
from the literature (Table 6.1). Equations used in the construction of the PBPK model 
are described in the methods section of Chapter 2 (section 2.2).  
The dosing regimen for each therapeutic agent was simulated according to avail-
able clinical studies. Medroxyprogesterone was validated for a single 150 mg LAI 
formulation for 12 weeks. Pharmacokinetic plasma concentration-time curve and 
available Cmax value were used as reference [254]. Olanzapine reaches steady-state 
after 2-3 months, hence the fourth 4-weekly 300 mg injection was validated against 
the clinical pharmacokinetic curve and the pharmacokinetic parameters Cmax, AUC 
and Cav (average concentration over the duration of the injection) were used to opti-
mise the release rate [255]. Paliperidone is initially administered through the deltoid 
muscle, so the pharmacokinetic parameters Cmax, AUC and Cav for the 4
th deltoid in-
jection were used for the optimisation process [256]. Risperidone is a prodrug and 
converts to its major active metabolite – paliperidone. Available pharmacokinetic data 
in literature constitutes combined data of both risperidone and paliperidone. Hence 
the PBPK model was designed to accommodate the combination of both drugs and 
its pharmacokinetic data was validated using the published clinical data. Patients with 
a pre-administered oral dose of 2 mg OD for 4 weeks continued administration of 2 
mg OD for further 3 weeks and 1 mg OD on the 4th and 5th week. Additionally, a 
biweekly IM LAI injection of 25 mg starting on day 8 and ending on day 64 was 
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administered. An oral dose of risperidone was not administered on the day of the in-
jection. The optimisation was conducted using the pharmacokinetic curve of 25 mg 
IM LAI administered on day 36 [257].   
Table 6.1 Physicochemical parameters of long-acting formulations used for the 
validation of the PBPK model 
  MPA Olanzapine Paliperidone Risperidone 
Molecular weight 344 312 426 410 
log Po:w 3.5 [239] 3.39 [241] 1.76 [243] 2.63 [245] 
Protein binding 90 % [239] 93 % [241] 74 % [243] 90 % [245] 
pKa 12.7 [239] 14.17 [241] 13.74 [243] 8.76 [245] 
R †0.86 †2.7   0.8 [258]  0.67 [189] 
PSA (Å2) 54.37 [239] 30.87 [241] 82.17 [243] 61.94 [245] 
HBD 1 [239] 1 [241] 1 [243] 0 [245] 
Clearance (L/h) 
38 ± 7.6 
[259]  -  1.53 ± 0.255 [258] 
- 
Renal clearance (L/h) -  -  3.19 ± 0.637 [258] - 
Clint2D6 - - - 25.2 [260] 
Clint3A4 - - - 10.45 [260] 
Clapp - 85 ±17 [241] - - 
R – blood-to-plasma ratio, PSA – polar surface area, HBD – hydrogen bond donors, 
Clint2D6, 3A4 – intrinsic clearance (µl/min/mg of microsomal protein), Clapp – apparent 
clearance (L/h), † predicted using correlation using molecular descriptors from Paixao et al. 
2009 [189] 
 
The pharmacokinetic curve of the clinical formulation was digitalised using an 
open source software – PlotDigitizer (v.2.6.8, Soundforge.net). The data obtained 
from this tool was exported into Simbiology (MATLAB v.2013b) and used as a ref-
erence to simulate the pharmacokinetics by varying the release rate. A range of release 
rates were simulated using the PBPK model. Plasma concentration of an average in-
dividual was correlated using digitalised clinical data points against PBPK predicted 
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data and release rate with the best coefficient of determination (R2) was selected. The 
simulated pharmacokinetics obtained using the release rate with the highest R2 was 
additionally compared against clinical data and the mean predicted pharmacokinetic 
parameters AUC, Cmax, Ctrough and Cav values deviated less than ± 100 % from the 
reported mean clinical values. 
In vitro release rates obtained from experimental data for static and dynamic re-
lease experiments (reported in section 5.3) and derived release rate from clinical data 
obtained using PBPK models were correlated. A linear correlation was established 
from the experimental and PBPK data. The regression equation obtained from the 
correlation is reported in the results section (section 6.3).  
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6.3. Results 
6.3.1. Quantification of release rate through PBPK modelling 
Linear regression was performed for the pharmacokinetic curve of the clinical data 
points obtained from the literature against simulated data points by varying the release 
rates in the PBPK model. The rest of the physicochemical and drug specific parame-
ters were kept constant in order to identify the optimal release rate. Various release 
rates and the regressions obtained for simulated pharmacokinetics against clinical data 
is shown in Figure 6.1. The optimal release rates with the best R2 is shown in Table 
6.2. 
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c)
 
d)
 
Figure 6.1   Release rate vs. regression value across various release rates for the four 
LAIs. a) Medroxyprogesterone acetate, b) olanzapine, c) paliperidone d) active moi-
ety of risperidone 
Table 6.2 Best coefficient of determination and the corresponding release rate 
for the four drugs 
  PBPK release rate (h-1) Correlation coefficient 
Medroxyprogesterone 0.0021 0.9911 
Olanzapine 0.00051 0.7561 
Paliperidone 0.0006 0.8420 
Risperidone 0.0062 0.7943 
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Pharmacokinetic validation of simulated data against clinical data for the four 
compounds is shown in Table 6.3a,b and the validation of predicted vs. clinical phar-
macokinetic curve is shown in Figure 6.2. PBPK modelling of medroxyprogesterone 
returned an optimal release rate of 0.0021 h-1 for a single 150 mg IM dose adminis-
tered for 12 weeks. The simulated Cmax had a deviation of -10.8 % from the mean 
clinical value [254]. For olanzapine, a release rate of 0.00051 h-1 was observed for a 
300 mg IM 4-weekly dose at steady state. PBPK simulated Cmax, Cav and AUC had a 
deviation of -6.8 %, -1.4 % and +0.1 % respectively from the mean clinical value 
[255]. Paliperidone was validated against the 4th deltoid 100 mg IM injection where 
the simulated Cmax, Cav and AUC deviated from the mean clinical value by -3.4 %, 
+2.4 % and +4.3 % [256]. The optimal release rate for paliperidone was observed to 
be 0.0006 h-1. The third IM injection of 25 mg risperidone LAI was validated against 
the clinical data with an observed release rate of 0.0062 h-1. The mean simulated Cmax, 
Ctrough, Cav and AUC were +66.5 %, -39.8 %, +30.4 % and +30.7 % from the mean 
clinical value. 
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b) 
 
c) 
 
d) 
 
Figure 6.2 Comparison of simulated vs. clinical pharmacokinetic curve of a) medrox-
yprogesterone acetate, b) olanzapine, c) paliperidone and d) active moiety of risperi-
done 
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Table 6.3a Summary of simulated and clinical pharmacokinetics for commercially available LAI and the optimised release rates 
using the PBPK model 
Cmax - maximum plasma concentration expressed in ng/ml, Ctrough – trough plasma concentration expressed in ng/ml, Cav – average 
plasma concentration in ng/ml, AUC – area under the curve expressed in ng x h/ml 
 
 
Simulated Clinical 
 
Cmax Ctrough AUC Cav Cmax Ctrough AUC Cav 
Medroxyprogesterone 7.4 ± 1.6 0.11 ± 0.03 3661 ± 799 1.9 ± 0.4 8.3 ± 3.16 [254] - - - 
Olanzapine 36.9 ± 8.7 - 18914 ± 4251 27.7 ± 6.2 39.6 (45.2 %) [255] - 18900 (44 %) [255] 28.1 (44 %) [255] 
Paliperidone 28.4 ± 5.4 - 14704 ± 2474 21.6 ± 3.6 29.4 ± 14.4 [256] - 14103 ± 5837 [256] 21.1 ± 8.8 [256] 
Risperidone 37.8 ± 5.9 6.8 ± 1.5 6932 ± 1313 20.6 ± 3.9 22.7 ± 9.2 [257] 11.3 ± 4.5 [257] 5303 [257] 15.8 [257] 
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Table 6.3b The percentage difference between the simulated and clinical phar-
macokinetics 
 
A summary of release rates obtained from in vitro experiments and optimised re-
lease rates using PBPK models is shown in Table 6.4. From Table 6.5 it can be ob-
served that the ratio of static and dynamic release rates for all the four formulations 
was <0.2 indicating a higher release of drug in dynamic system which utilizes higher 
volume of media (6 ml vs 720 ml). However, the comparison of in vitro and PBPK 
release rates indicate a closer similarity to the static release than dynamic release with 
three data points having similar ratio in static compared to two with dynamic release 
experiments implying that there is a higher correlation with static release experi-
mental method in identifying the PBPK release rate.  
Table 6.4 Release rates (expressed as h-1) obtained from in vitro and in silico 
methods 
  Static release Dynamic release PBPK simulated 
Medroxyprogesterone 0.0010 0.0177 0.0021 
Olanzapine 0.0298 0.7100 0.00051 
Paliperidone 0.0002 0.7670 0.0006 
Risperidone 0.0035 0.0179 0.0062 
 
 
% difference - simulated vs. clinical 
 
Cmax Ctrough AUC Cav 
Medroxyprogesterone -10.8 - - - 
Olanzapine -6.8 - -52.8 -1.4 
Paliperidone -3.4 - -66.6 2.4 
Risperidone 66.5 -39.8 30.7 30.4 
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Table 6.5 Comparison across in vitro and simulated release rates  
  Static/Dynamic  Static/PBPK Dynamic/PBPK 
Medroxyprogesterone 0.05650 0.48 8.43 
Olanzapine 0.04197 58.32 1389.43 
Paliperidone 0.00026 0.33 1278.33 
Risperidone 0.05650 0.56 2.89 
 
6.3.2. IVIVE 
IVIVE between static release experimental and simulated release rates is shown 
in Figure 6.3. The coefficient of determination obtained from the best fit line is 0.14 
which is an unreliable correlation between in vitro and in silico release rate. A nega-
tive correlation between in vitro and PBPK release rate does not inform the correlation 
correctly. However, if the significant outlier (P < 0.05) value of olanzapine is re-
moved, an agreeable correlation (R2 = 0.9993), where the PBPK release rate is directly 
proportional to in vitro release rate was observed. The regression equation obtained 
from the correlation of in vitro and in silico release rate is as follows: 
𝑦 = 1.6834𝑥 + 0.0003       (1) 
where x is in vitro release rate and y is simulated release rate in h-1.  
 
Figure 6.3 Correlation between in vitro static release experiments and in silico release 
from PBPK model 
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Figure 6.4 IVIVE of in vitro and in silico release rate with the exclusion of olanzapine 
 
The correlation obtained using dynamic release experiments and in silico models 
has a regression value of 0.6024. The equation for IVIVE is as follows: 
𝑦 = −0.005𝑥 + 0.0042     (2) 
where x is the in vitro release rate and y is the in silico release rate 
 
Figure 6.5 Correlation between in vitro dynamic release experiments and in silico 
release from PBPK model 
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The negative correlation indicates that the PBPK release rate or the in vivo human 
release rate decreases as the in vitro release rate increases. Theoretically, the in vitro 
and in vivo release rates are directly proportional since the in vitro experiments mimic 
the in vivo environment. This implies that the obtained correlation from dynamic re-
lease experiments contradicts the relation between in vitro and in vivo experiments. 
Hence the dynamic release experiments are inconclusive at this stage due to limited 
number of data points.  
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6.4. Discussion 
IVIVE application of LAI formulations may accelerate the development of future 
drug formulations, supporting the extrapolation of in vitro data to predict in vivo re-
sults.  IVIVE could help predict drug pharmacokinetics of various novel formulations 
in minimal time and assist in identifying the best LAI formulation through PBPK 
modelling. The current chapter focused on informing the mathematical correlation 
between in vitro and in silico release rates obtained using four commercially available 
formulations. 
In this study, drug diffusion from the formulation into blood plasma was assumed 
to obey first-order kinetics. From Figure 6.2 and Table 6.3 it can be observed that 
PBPK simulated pharmacokinetic curve was similar to clinical curve and the pharma-
cokinetic parameters were ± 100 % from mean reported clinical values. The simulated 
Cmax of risperidone active moiety was higher compared to the clinical curve, however 
the pharmacokinetic parameters were < ±100% from the clinical value, hence the 
model was assumed to have higher predictive value.  
Comparison of static and dynamic release rates (Table 6.5) indicate that release 
rate across different methods is comparable (ratio > 0.04) for microformulations. Hor-
izontal agitation of the static dialysis system could have led to sedimentation of for-
mulation in the donor compartment restricting the total surface area in contact with 
media leading to slower release rate. 
Static-to-PBPK release rate ratio is closer to one for three formulations except for 
olanzapine (Table 6.5). This phenomenon could be explained due to higher water sol-
ubility of olanzapine formulation compared to others. Water solubility is a key pa-
rameter in drug release for LAI. Solubility enhancers would be necessary for low 
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soluble compounds to achieve an increase in drug release and more stable micro- or 
nanoparticles are required to restrict drug release for highly soluble compounds. Re-
stricted release was observed with paliperidone nanoformulation due to its smaller 
particle size and lower protein binding. Although physical parameters affect drug re-
lease widely across in vitro experiments, appropriate conditions are met in vivo to 
achieve necessary plasma concentrations.  
Higher release rate (ratio >1) was obtained for all the formulations during dynamic 
release experiments compared to in silico release rate which could be explained due 
to the large amount of media used and greater extent of agitation during media circu-
lation (Table 6.5). Higher surface area of nanoparticles could trigger greater drug re-
lease observed with the paliperidone formulation.  
Exclusion of olanzapine led to a better regression and a positive correlation. This 
however reduces the number of formulations used for IVIVE to three (Figure 6.4). 
Dynamic release experiments returned a negative correlation which is counterintui-
tive. Various factors such as particle size, protein binding, drug solubility, surface 
area in contact, agitation, volume of media led to a wide variation in release rates. 
Particle size and total surface area of particles in contact are two interdependent pa-
rameters. Larger particle size leads to greater release for porous particles but as the 
particles become smaller the total surface area increases which further improves the 
overall drug release. Presence of proteins in the media favours drug release which 
could be observed from Table 5.3. Lack of agitation leads to accumulation of the 
formulation thus decreasing the overall surface area in contact with the media. Higher 
volume of media avoids saturation thereby favouring drug release from the formula-
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tion (Table 5.3). The effect of these factors could be studied in detail with more num-
ber of formulations to obtain a better understanding of the relation between in vitro 
and in vivo release rate. 
The evaluation of a small number of formulations could lead to inaccurate corre-
lation thus giving biased IVIVE values for novel formulations. In other studies, large 
numbers of drugs have been evaluated to obtain a reliable IVIVE. For example, 25 
CYP3A molecules were used to predict the intestinal first pass metabolism [57] and 
29 drugs were used to predict the systemic clearance [261]. Since the number of clin-
ically used water based LAI micro- and nanoformulations is very limited, future re-
search will be essential to have a more comprehensive evaluation of this IVIVE ap-
proach. However, the presented data provides a platform into which other future 
agents can be included, as they are developed.
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HAART has improved life expectancy of HIV+ patients. However current thera-
peutic strategies do not eradicate the virus from the human body due to a variety of 
reasons - targeting CD4 T-cells that regulate immunity, existing therapies failing to 
eliminate HIV provirus, poor drug penetration in sanctuary sites and unexplored ques-
tions lying in the human genome to confront human endogenous retroviruses 
(HERVs) [50, 262]. Consequently, HIV patients are expected to continue HAART 
indefinitely and these regimens are currently administered as oral formulations, based 
on a daily dosage of multiple ARVs. Several ARVs have poor oral bioavailability, 
which results in a substantial portion of the dose unable to reach target sites that lead 
to increase in total daily drug intake to achieve therapeutic exposure thereby increase 
the total cost for therapy [73, 263]. Additionally, pill fatigue following chronic ad-
ministration of oral formulations can result in suboptimal adherence, increasing the 
chance of developing resistance against prescribed therapy. Suboptimal adherence 
can not only lead to failure in treatment but also low protection rates in the case of 
PrEP. Reduced frequency of drug administration by prolonging treatment duration 
could help improve adherence. Recently LA formulations have been developed to 
support APIs extend the period of therapy through injectable SC or IM depot, thus 
effectively addressing the problem of oral suboptimal adherence. The IM or SC ad-
ministration bypass the intestinal barrier and hepatic first-pass metabolism thus im-
proving bioavailability, reducing the total dose and overall cost of therapy to achieve 
therapeutic exposures [88]. 
Currently, evaluation of IM formulations is directly performed in vivo in animals, 
since a validated experimental in vitro system has not been developed to characterise 
drug release pattern for LA formulations [86, 264]. A key challenge in the develop-
ment of this type of experimental test is the evaluation of the predictive value for in 
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vivo pharmacokinetics. In vitro systems to predict pharmacokinetics of novel LA for-
mulations represent an essential tool to inform the formulation’s rational design with 
optimal exposure. The application of these experimental methods could reduce the 
cost and time of screening for large library of candidate formulations. The overall aim 
of this thesis was to develop experimental and computational methods to support the 
design of LA nanoformulations. A whole-body PBPK model has been applied to iden-
tify theoretical optimal doses and release rates of novel formulations in adults and 
paediatrics and experimental in vitro systems to characterise the formulation release 
rate were developed to extrapolate the pharmacokinetics in humans. 
PBPK modelling as described in Chapter 1 is a predictive computational tool that 
assists in evaluating the pharmacokinetics through integration of physicochemical and 
ADME properties. Whole-body PBPK models integrate equations that describe anat-
omy and physiology of organisms (i.e. rat, mouse and human) and pharmacokinetic 
processes such as absorption, distribution, metabolism and elimination to simulate 
drug accumulation across various tissues and organs in the body.  
An adult PBPK model was developed using Simbiology, a product of MATLAB. 
Version 2013b of the tool was used for designing the model due to its ease of use with 
the interactive user interface and low number of encountered errors during its opera-
tion. The PBPK model was constructed using various anthropometric equations avail-
able from literature describing weights and volumes of organs, blood flow-rates, drug 
distribution kinetics across tissues etc., described earlier in Chapter 2. The PBPK 
model was rigorously tested and anatomical and physiological values were cross 
checked with literature data before using it to determine drug pharmacokinetics. The 
PBPK model was further extended to include anatomy and physiology of children and 
adolescents. Since the growth pattern varies widely during development of paediatric 
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individuals, validation was performed at different age groups to ensure confidence in 
the generated virtual individuals (Chapter 3).  
The majority of dose finding studies are conducted in healthy volunteers and often 
exposure in patients or individuals with specific physiological characteristics can vary 
significantly. Use of a whole-body PBPK model could assist the prediction of phar-
macokinetics in subpopulations of patients or individuals who are not commonly in-
cluded in clinical studies. Anatomical and physiological characteristics can vary 
widely across individuals, therefore a comprehensive description of correlation be-
tween anthropometric and anatomical factors have been included in the models, to 
provide a realistic anatomical description of the virtual patient. To further capture the 
potential predictability in patient populations, variability was added from the litera-
ture to each equation describing correlation between factors.  
The developed PBPK models were validated against their oral counterparts and if 
available against IM formulations as well, prior to the prediction of optimal dose and 
release rates. Earlier published papers used a 2-fold range from the clinical mean as 
the acceptable validation range [152]. In the present study, a stringent validation range 
of 0.5-fold was used to improve the accuracy of predictions.  
Currently, over 25 ARV drugs are marketed for HIV treatment but only a preferred 
few are used due to their advantages in effectively restricting the viral replications 
and mutations in infected individuals. To inform the design of LA nanoformulations 
for a weekly or a monthly administration, eight commonly used ARVs were selected. 
PBPK models were developed and validated against existing available clinical data 
for oral formulations in adult population for the chosen ARVs. To inform the first-
order release rate kinetics of the nanoformulation, an additional IM compartment was 
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introduced in the PBPK model. Doses and release rates were optimised in Chapter 2 
according to the mentioned cut-off values.  
Ethical concerns hinder the dose optimisation studies in children and adolescents. 
Majority of doses are scaled down from adults and since evidence shows that anatomy 
and physiology of children varies widely from adults. Anthropometric equations were 
validated in Chapter 3 for various anatomical and physiological parameters by age to 
accommodate the age related changes in children and adolescents. WHO recommends 
use of different doses for children and adolescents across weight groups. To predict 
the optimal doses for different weight categories of paediatric individuals, in Chapter 
4, validated PBPK models were used for existing adult LAI formulations of cabo-
tegravir and rilpivirine. 
The constructed PBPK models for adults and children could be used as a platform 
to evaluate the pharmacokinetics of new chemical entities. Using the provided data in 
this thesis, long-acting potential of ARVs was informed that could be used to inform 
appropriate design of formulations for their respective route of administration. The 
simulated data using the PBPK model could act as a reference for clinical studies of 
long-acting formulations in adults and children. Drugs such as tenofovir alafenamide, 
etravirine, rilpivirine are not prescribed in children less than 6 years [265]. The de-
signed paediatric PBPK model could be applied to ARVs not evaluated in younger 
children yet, to inform appropriate doses of existing oral formulations. 
Improved reliability on in vitro data ensures less dependency on clinical data to 
predict drug pharmacokinetics in humans for novel formulations. Preliminary screen-
ing of a formulation library during drug discovery and formulation phase could speed 
up the optimisation process. Three in vitro experiments were conducted using four 
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different clinical LAI formulations. Appropriate release rates were identified for the 
four formulations in Chapter 5. PBPK models for the four formulations were devel-
oped and the optimal release rate were identified in Chapter 6. Mathematical expres-
sions to compute IVIVE from the in vitro experiments and PBPK simulations were 
also described. 
Although the reported PBPK models could inform the pharmacokinetics of the 
desired therapeutic agents, it has its disadvantages. The models are only as good as 
the data that is plugged in. They completely rely on the credibility of the in vitro data 
and one of the problems is the use of different in vitro methods to compute the same 
parameter. For example, caco-2 permeability could be evaluated using radioactive 
and non-radioactive methods [57, 266]. Also different experimental methods use dif-
ferent transepithelial electrical resistance (TEER) values to check the integrity of the 
monolayers [74, 266]. The effective permeability scaled from caco-2 permeability 
values was derived using just one type of experimental method. Using the same al-
lometric equations for data derived from different experimental methods could reduce 
the reliability of the in vitro data. This necessitates the standardisation of methods that 
could generate reliable in vitro data by following the same experimental setup univer-
sally. Till date, transporter data could not be scaled up due to the poor understanding 
of the factors involved in the process [267]. Various processes such as metabolism, 
absorption and transporter activity occurring simultaneously complicates the inde-
pendent understanding of each of these processes to derive correlations and are yet to 
be optimised [268, 269]. 
Limitations reported during dose optimisation studies using the PBPK model 
could be addressed in future studies. Transporter data refines the PBPK model by 
informing key processes involved in intestinal absorption, drug distribution across 
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tissues, clearance and elimination patterns. Introduction of lymphatic system in the 
PBPK model could improve the predictions of lipophilic drugs which inform kinetics 
between various lymphatic nodes and blood circulation system. Although drug distri-
bution in various tissues is not of a particular interest in monitoring HIV virus, math-
ematical description of organ and tissue physiology could shed a light on penetration 
ability and pharmacodynamics of drugs that require targeted treatment. The experi-
mental methods could not identify the independent effect of each of the drug physi-
cochemical characteristics and various other parameters across release experiments. 
Further studies to identify the influence of each of these parameters on drug release 
could help derive a reliable mathematical correlation between in vitro and PBPK re-
lease rate. 
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Figure 7.1 Summary of the various applications of a physiologically based pharmacokinetic model [111]
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Optimisation of dose and release rates of novel formulations is only one of the 
many applications of PBPK modelling (Figure 7.1). In this thesis, dose evaluation 
was informed for healthy adult and paediatric individuals, however special popula-
tions such as elderly, pregnant women, organ impairments could also be evaluated 
through PBPK models. For example, drugs such as alfentanil, lidocaine, theophylline 
and levetiracetam were evaluated in different classes of liver cirrhosis patients [216]. 
Another study evaluated the disposition of midazolam in adults, elderly patients and 
compared against clinical data [270]. Genetic variation among individuals is normal 
and may contribute to the change in drug pharmacokinetics which has been evaluated 
in patients administered with efavirenz having low, medium and high systemic drug 
clearance depending on 516 GG, GT and TT polymorphisms [249]. Drug penetration 
in tissues is one of the most complicated tasks to analyse in humans. Identification of 
drug distribution across different organs and tissues could be evaluated using PBPK 
models to further improve the understanding of ADME processes. Curley et al. in-
formed efavirenz drug penetration in CNS tissues using a PBPK model and validated 
against clinical data from rodents and humans [271]. Penetration of levofloxacin was 
identified and compared with in vivo rat data in various tissues such as heart, liver, 
kidney and spleen. Models were extrapolated using rat data to inform the pharmaco-
kinetics and tissue distribution in humans [272]. Opportunistic infections such as tu-
berculosis, hepatitis reportedly infect HIV+ patients due to their weak immune sys-
tem. Infected patients administer multiple dosing regimens to suppress these infec-
tions. Drug interactions might occur during administration of multiple regimens due 
to the same metabolising enzyme involved in drug metabolic clearance. PBPK models 
could compute the effect and extent of drug-drug interactions (DDIs) on plasma phar-
macokinetics and assist in dose adjustments accordingly. DDIs between efavirenz, 
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CYP inducers and inhibitors such as montelukast, paclitaxel, pioglitazone and rep-
aglinide were evaluated and appropriate dosing adjustments were recommended 
[273]. Extent of interaction between efavirenz and various antidepressants was re-
ported in another study [114]. Numerous applications of a PBPK model could make 
it an innovative pharmacological tool to predict and inform pharmacokinetics in indi-
viduals potentially simplifying ART. 
In summary, a PBPK model was developed both for adults and paediatric patients 
to inform the dose and release rate of LAI nanoformulations. Novel experimental 
methods were developed to inform the in vitro release rate of LA formulations. The 
developed in vitro and in silico models could assist in informing the pharmacokinetics 
of novel formulations thus improving the problem of suboptimal adherence and re-
ducing time in dose optimisation and cost of therapy. 
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